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(A) Epidemiology of Osteoporosis
1. General considerations
1.1 Osteoporosis represents a major public health 
problem worldwide, and this burden is growing 
with increasing life expectancy and ageing of the 
world’s population.
1.2 It has been projected that more than half of all hip 
fractures in the world, amounting to 3250 million 
cases, would occur in Asia, mostly China, by the 
year 2050.1
2. Hip fracture incidence in Hong Kong
2.1 Between 1966 and 1985, the age-specific incidence 
of hip fracture increased by 300% in women and 
200% in men aged 50 years or older, concomitant 
with urbanisation and adoption of a more sedentary 
lifestyle in Hong Kong.2
2.2 A subsequent territory-wide survey showed that 
the age-specific incidence of hip fracture had 
levelled off between 1985 and 1995 (Table 1).3 
2.3 Recent data obtained from the Clinical Data 
Analysis and Reporting System of the Hospital 
Authority show that the age-specific incidence of 
hip fracture has demonstrated a downward trend 
(almost 50% decline) in subjects aged 50-59 years 
in both sexes, but remained stable for other age 
groups between 1995 and 2004; most hip fractures 
still occurred in men and women aged 80 years and 
older (Fig 1).4
2.4 The reasons for this improvement are unclear. It has 
been postulated that the following factors might be 
involved4:
 (i) increase in public awareness of prevention of 
osteoporosis leading to changes in lifestyle, 
including higher dietary calcium intake, 
increased physical activity and sun exposure
 (ii) use of hormone replacement therapy (HRT) 
by peri- and postmenopausal women
 (iii) availability of anti-osteoporosis drugs
 (iv) better community awareness of fall prevention 
and promulgation of Tai Chi classes at the 
district level
 (v) secular increase in body weight and height 
due to better nutrition and medical care
2.5 Despite stabilisation of the age-specific incidence 
rates, the absolute number of hip fractures is 
anticipated to continue to grow exponentially. 
FIG 1.  Age-specific hip fracture rates in Hong Kong from 1995 to 2004 (per 100 000 population): age (a) 50-59 years; (b) 60-69 
years; (c) 70-79 years; and (d) 80 years or older4
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Table 1. Age-specific incidence rates for hip fracture in Hong Kong (per 100 000 population)2
Age-group (years) No. of women (per 100 000) No. of men (per 100 000)
1966 1985 1991 1995 1966 1985 1991 1995
50-59 22 32 26 26 16 28 27 22
60-69 54 135 112 108 67 54 73 71
70-79 173 501 581 581 224 339 321 308
≥80 716 1521 1916 2129 321 1156 1191 1075
50-59 years
70-79 years
60-69 years
≥80 years
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Assuming no increase in age-specific incidence 
rates, the total number of hip fractures in the year 
2015 are estimated to be 5293 and 2349 in Hong 
Kong women and men, respectively.5
3. Vertebral fracture incidence in Hong Kong
3.1 Accurate age-adjusted incidence for vertebral 
fracture is lacking because only about one-third of 
all vertebral fractures noted on radiographs come 
to medical attention. 
3.2 The local prevalence of vertebral fracture, defined 
by vertebral height ratio reduction by 3 or more 
standard deviations (SDs), was 30% in women 
and 17% in men aged 70-79 years. These rates are 
much higher than those in Taiwan and Mainland 
China, and are comparable to those in American 
Caucasians.6
4. Health impact of osteoporosis
4.1 Osteoporotic fractures have devastating health 
consequences through their association with 
increased morbidity and mortality, and they pose a 
considerable burden to the health care system.
4.2 The most common osteoporotic fractures are 
fractures of the spine, hip, and distal forearm.
4.3 Up to 20% of hip fracture patients die within 1 year 
of the event, 40% of the survivors are unable to 
walk independently, 60% require assistance in at 
least one essential activity of daily living, and 80% 
are unable to perform at least one instrumental 
activity of daily living; 27% require long-term 
nursing home care.7 A prospective 5-year Australian 
study identified infections and cardiac diseases to 
be the main causes of excess mortality during the 
first 9 months after hip fracture in institutionalised 
elderly.8 
4.4 Vertebral fractures are also associated with excess 
mortality, which seems to increase progressively 
after diagnosis of the fracture with an observed 
5-year survival of 18-35% lower than expected.9
4.5 Regarding the public health perspective, the vast 
majority (95%) of the direct cost of osteoporosis is 
incurred by acute management and rehabilitation 
of bone fracture and related complications.
4.6 In Hong Kong, the total cost for treatment of hip 
fractures was US$19 million in 1995. According to 
the report of the Hospital Authority in 1996, the 
acute hospital care cost for hip fractures amounted 
to 1% of the total annual hospital budget, or US$17 
million, for a population of 6 million.5
(B) Definitions of Osteoporosis
1. Medical definition of osteoporosis
1.1 Osteoporosis was first defined medically in a 
Consensus Development Conference in 1991 as a 
progressive systemic skeletal disease characterised 
by low bone mass and microarchitectural 
deterioration of bone tissue, with a consequent 
increase in bone fragility and susceptibility to 
fracture.10
1.2 Increased understanding of the disease has changed 
the concept of osteoporosis such that the National 
Institutes of Health Consensus Development 
Panel in 2001 re-defined osteoporosis as a skeletal 
disorder characterised by compromised bone 
strength predisposing a person to an increased risk 
of fracture. Bone strength reflects the integration of 
two main features: bone density and bone quality. 
Bone quality refers to other skeletal properties, 
including bone size, micro-architecture, rate of 
bone remodelling (turnover), mineralisation, and 
damage accumulation (microfractures).11
2. Operational definition of osteoporosis
2.1 The 1994 World Health Organization (WHO) 
diagnostic criteria are currently employed in 
clinical practice for defining a bone mineral density 
(BMD)-based diagnosis of osteoporosis. Based on 
the T-scores derived from BMD measurements at 
the lumbar spine or proximal femur, the diagnosis 
is classified as normal, osteopenia, or osteoporosis 
(Table 2).12,13
3. Clinical definition of osteoporosis
3.1 For practical purposes, if a postmenopausal woman 
or elderly man has sustained a low-trauma or low-
energy fracture, defined as a fracture that occurs 
from a fall from standing height or lower, a diagnosis 
of osteoporosis can be clinically established.
(C) Diagnosis of Osteoporosis
1. General considerations
1.1 Bone strength is an integration of bone density 
and bone quality. As methods of measuring bone 
quality are not available for general clinical use, 
the diagnosis of osteoporosis has to rely on BMD 
measurement prior to the development of a fragility 
fracture.
2. Dual-energy X-ray absorptiometry 
2.1 Dual-energy X-ray absorptiometry (DXA) is 
currently regarded as the gold standard for 
diagnosis of osteoporosis; it is the only means for 
diagnostic classification according to the WHO 
diagnostic criteria.12-15
2.2 DXA measures BMD in gram per cm2, defined as the 
integral mass of bone mineral per unit projected 
area.
2.3 Central DXA at the hip and the spine are the 
recommended sites for a DXA scan. BMD 
measurements at these regions of interest are the 
Table 2. The World Health Organization criteria for diagnosis of osteoporosis13
Diagnostic category Definitions
Normal BMD within 1 SD of the young adult mean (T-score ≥ –1.0)
Osteopenia BMD >1 SD below the young adult mean, but <2.5 SD below this value (T-score < –1.0 and > –2.5)
Osteoporosis BMD ≥2.5 SD below the young adult mean (T-score ≤ –2.5)
Severe (established) osteoporosis BMD ≥2.5 SD below the young adult mean (T-score ≤ –2.5) in the presence of ≥1 fragility fractures
* BMD denotes bone mineral density, and SD standard deviation
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best predictor of fracture risk for the corresponding 
sites.16
2.4 BMD measurement is expressed in a SD unit called 
the T-score, which is the difference between the 
measured BMD and the mean of a young healthy 
adult (peak bone mass) reference population, 
matched for gender and ethnicity, and normalised 
to the SD of that population. The definitions of 
osteoporosis, osteopenia, and normal BMD based 
on T-score values are intended to identify patients 
with high, intermediate and low fracture risks 
respectively.12,13
 
T-score  =
 Measured BMD – young adult mean BMD
      Young adult population SD
2.5 The Z-score is a similar concept to the T-score, but 
comparison is made to a healthy age-, gender- and 
ethnicity-matched population.
 
Z-score =
 Measured BMD – age-matched mean BMD
      Age-matched population SD
2.6 The Z-score is not used to define osteoporosis. The 
Z-score is useful for identification of individuals 
with BMD lower than expected for their age, and 
for determination of fracture risk compared with 
their peers. Low Z-scores (< –2.0) should prompt a 
search for secondary causes of osteoporosis.
2.7 To allow comparison across different populations, 
the WHO recommended using the third United 
States (US) National Health and Nutritional 
Examination Survey (NHANES III) reference 
database derived from Caucasian women aged 
20-29 years as a standardised international hip 
reference for women and men of all ethnic groups.17 
However, in view of the marked difference in body 
size between Caucasians and Asians, the use of the 
NHANES III database might produce a distorted 
T-score in Asian subjects. Asian normative databases 
for diagnosing osteoporosis in Asian subjects are 
recommended. Similarly an ethnic male normative 
database should be used to evaluate Asian men, if 
available.18
2.8 The indications for BMD testing recommended by 
the Asia-Pacific Panel Consensus Meeting of the 
International Society for Clinical Densitometry 
are18: 
 (i) women aged 65 years or older
 (ii) postmenopausal women younger than 65 
years with risk factors for fracture (Table 3)
 (iii) peri-menopausal women with clinical risk 
factors (Table 3) or who are taking medications 
that predispose them to skeletal risk (Table 4)
 (iv) men aged 70 years and older
 (v) men younger than 70 years with clinical risk 
factors for fracture (Table 3)
 (vi) adults with a fragility fracture
 (vii) adults with a disease or condition associated 
with low bone mass or bone loss (Table 4)
 (viii) adults prescribed medications associated with 
low bone mass or bone loss (Table 4)
 (ix) anyone being considered for pharmacological 
therapy for fracture prevention
 (x) anyone being treated for osteoporosis to 
monitor treatment effect
 (xi) anyone not receiving therapy in whom 
evidence of bone loss would lead to treatment
2.9 Advantages of DXA: DXA has a very low radiation 
dose comparable to an average daily background 
radiation, short scanning time, and good precision.
2.10 Potential sources of error include14:
 (i) concomitant osteomalacia
 (ii) osteoarthritic changes of the spine and hip
 (iii) soft tissue calcification, notably aortic 
calcification
 (iv) overlying metallic objects
 (v) contrast media
 (vi) prior fracture
 (vii) severe scoliosis
 (viii) extreme obesity or presence of ascites
 (ix) vertebral deformities
 (x) inappropriate reference database
 (xi) inappropriate measurement technique 
(calibration, region selection, acquisition 
mode and positioning)
2.11 Current recommendations for clinical use of DXA 
are18:
 (i) diagnosis of osteoporosis
 (ii) assessment of fracture risk
 (iii) monitoring of changes in BMD over time
2.12 The WHO cut-off diagnostic criterion of T-score 
≤ –2.5 applies only to BMD measurements by DXA, 
and cannot be indiscriminately applied to other 
technologies such as quantitative ultrasound (QUS) 
or computed tomography.
2.13 The T-score obtained from DXA provides a 
diagnostic threshold but not a treatment threshold, 
which should take into account the absolute 
fracture risk (refer to Section E: Assessment of 
Fracture Risk on page 11).
3. Quantitative ultrasound 
3.1 QUS is a non-invasive, portable, inexpensive, and 
radiation-free technology for measuring bone 
properties at peripheral skeletal sites.
3.2 QUS does not measure BMD but measures other 
parameters of bone properties, namely broadband 
ultrasound attenuation or speed of sound at 
peripheral skeletal sites.
Table 3. Clinical risk factors for osteoporosis
Risk factor
Female sex
Increasing age
History of fragility fracture
Low body weight (<45 kg)
Family history of osteoporosis or fragility fracture
Premature menopause (before age 40 years) or early
menopause (age 40-45 years)
Low calcium intake 
Lack of exercise or sedentary lifestyle
Smoking
Excessive alcohol intake (≥3 standard drinks per day)
Lack of sun exposure
Prolonged immobilisation
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3.3 The correlation of QUS parameters with BMD 
measurements by DXA is relatively poor.
3.4 The T-score measured by QUS is not equivalent 
to that by DXA measurement and should not be 
used interchangeably to diagnose osteoporosis 
according to the WHO diagnostic classification.
3.5 The only validated skeletal site for the clinical use 
of QUS is the calcaneum. Validated calcaneal QUS 
devices can have good prediction for fracture risk 
and can help to identify patients at high or low risk 
of having osteoporosis.19
3.6 Given the limited precision of QUS and the lack of 
treatment data on peripheral skeletal sites, QUS 
should never be recommended for monitoring of 
bone loss or treatment response.19
3.7 With the wide general availability of DXA in Hong 
Kong, indiscriminate use of QUS for osteoporosis 
management is to be discouraged.
4. Quantitative computed tomography
4.1 BMD measured by quantitative computed 
tomography (QCT) is a true volumetric density in 
gram per cm3, in contrast to an areal density in gram 
per cm2 as measured by DXA.
4.2 QCT is available for BMD measurements at the 
spine, hip, forearm, and tibia. The term peripheral 
QCT (pQCT) defines the application of QCT to 
appendicular skeletal sites such as the forearm and 
tibia.
4.3 QCT is unique in that it can measure trabecular and 
cortical bone separately. Since trabecular volumes 
of interest are largely independent of degenerative 
changes in the spine, QCT may be considered 
when there are significant degenerative changes 
and deformities making the assessment of the 
spine by DXA suboptimal.20
4.4 Trabecular BMD measured by QCT of the spine 
can predict vertebral fracture in postmenopausal 
women as good as that measured by DXA, but not 
at other sites and not in men.19 pQCT of the radius 
can also predict the risk of fracture at the hip in 
postmenopausal women, but not at other sites and 
not in elderly men.20
4.5 As trabecular bone is more responsive than cortical 
bone to treatment interventions, QCT of the spine 
can be used for monitoring treatment changes.20
4.6 The use of QCT is limited by its higher precision 
error, high radiation dose, relatively high cost 
and, most importantly, limited medical evidence. 
Definitive advice on its use in clinical practice 
cannot be provided until more data become 
available.
5. Other technologies
5.1 Single or dual photon absorptiometry and single 
X-ray absorptiometry have largely been replaced by 
DXA.
5.2 Peripheral DXA (pDXA) is specifically designed to 
measure the BMD of peripheral skeletal sites at the 
forearm, finger phalanges, and calcaneus using DXA. 
The advantages of pDXA are that the instruments 
are smaller and more portable, requiring minimal 
space to operate, are less expensive, and have an 
extremely small radiation dose. Since the evidence 
for pDXA to predict fracture risk is not as substantial 
as that for central DXA and there is no evidence for 
it to be used for monitoring purpose, its role in 
clinical practice remains poorly defined.21
5.3 Plain radiograph of the spine should not be used 
to assess bone density owing to its low sensitivity, 
but it is useful for detecting subclinical vertebral 
fractures. Morphometric vertebral fracture 
can be easily assessed using the Genant visual 
Table 4. Common secondary causes of osteoporosis
Cause Disorder/drug class
Endocrine disorders Hyperthyroidism
Hyperparathyroidism
Cushing syndrome
Hypogonadism
Hyperprolactinaemia
Anorexia nervosa
Disorders of calcium metabolism Vitamin D deficiency
Hypercalciuria
Gastrointestinal disorders Primary biliary cirrhosis
Pancreatic diseases
Low acidity states: gastrectomy, gastric bypass, pernicious anaemia 
Haemochromatosis
Malabsorption syndrome: inflammatory bowel disease, coeliac disease
Medications Corticosteroids
Anticonvulsants
Proton pump inhibitors
Aromatase inhibitors
Thiazolidinediones 
Anticoagulants
Depo-medroxyprogesterone
Chemotherapy
Immunosuppressants
Excessive thyroxine replacement
Miscellaneous medical conditions Multiple myeloma
Thalassaemias
Rheumatoid arthritis
Stroke (hemi-osteoporosis)
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semiquantitative method.22
5.4 An alternative for vertebral fracture assessment is 
to have a DXA machine capable of forming a high-
resolution lateral image of the thoracolumbar spine 
and measuring vertebral height during concomitant 
evaluation of BMD measurement. Vertebral fracture 
assessment is an established low-radiation method 
for detection of prevalent vertebral fractures.23
6. Bone turnover markers 
6.1 Bone turnover markers (BTMs) are biochemical 
by-products of bone remodelling. Biochemical 
markers of bone formation and resorption provide 
information on the rates of bone turnover. Higher 
levels are associated with faster, and possibly 
greater, bone loss.
6.2 Bone resorption markers are mostly fragments of 
type 1 collagen released during osteoclastic bone 
resorption and are measured in the serum or urine; 
they include N-telopeptide (NTX), C-telopeptide 
(CTX), deoxypyridinoline (DPD), pyridinoline 
(PYD) and tartrate-resistant acid phosphatases 
(TRAP). Serum CTX and urine NTX are currently 
considered the best indices for assessment of bone 
resorption.24
6.3 Bone formation markers (BFMs) are proteins 
secreted by osteoblasts or by-products of type 
1 collagen deposition that are produced during 
the bone formation process, and are measured 
in the serum; BFMs include bone-specific 
alkaline phosphatase (bs-ALP), procollagen type 
1 N-propeptide (P1NP), procollagen type 1 C-
propeptide (P1CP) and osteocalcin. Serum P1NP 
appears to be the most sensitive marker of bone 
formation.25
6.4 Measurement of BTMs is subject to variability that 
can be classified as biological (pre-analytical) and 
analytical.
    6.4.1 Biological variability include age, gender, 
menopausal status, recent fractures, 
pregnancy, lactation, co-morbidities (thyroid 
disease, diabetes mellitus, impaired renal 
function, liver disease), drugs (glucocorticoids, 
anticonvulsants, heparin, gonadotropin 
hormone releasing hormone agonists), 
immobility, circadian variability, fasting status, 
and exercise.24,25
    6.4.2 Analytical variability is affected by processing 
of the specimen (collection, handling, and 
storage) as some BTMs are sensitive to 
temperature, ultraviolet light exposure and 
freeze/thaw cycles, and by the type of BTM 
and assay used.25,26
6.5 Currently, there is no role for these markers in the 
diagnosis of osteoporosis as there is substantial 
overlap in values for healthy and osteoporosis 
subjects.25,27 However, unexpected high levels 
of markers should raise the suspicion for other 
disorders associated with high bone turnover such 
as hyperthyroidism, hyperparathyroidism, Paget’s 
disease, and osseous metastases.
(D) Screening for Osteoporosis
1.1 Osteoporosis is regarded as an ‘asymptomatic’ 
disease and the diagnosis is usually made after a 
fracture.
1.2 There is no convincing evidence for the benefit of a 
population-based screening strategy applicable to 
the local situation.28
1.3 A case-finding approach by increasing physician 
awareness of the clinical risk factors for 
osteoporosis (Table 3) and, hence, deciding who 
should have further BMD assessment is more 
practicable than population-based screening. In 
general, there seems to be an additive effect of risk 
factors, in that the presence of more risk factors 
means a higher risk of osteoporosis.
1.4 The Osteoporosis Self-assessment Tool for Asians 
(OSTA) [Fig 2] is a simple clinic tool based on age 
and weight to evaluate the risk of osteoporosis 
in Asian women. The OSTA has been validated 
in eight Asian regions, including China, Hong 
Kong, Korea, Malaysia, the Philippines, Singapore, 
Taiwan, and Thailand.29,30 All women in the OSTA 
high-risk category should be recommended for 
BMD measurements (Table 5). The OSTA has 
subsequently been proven to be applicable to 
Asian men as well as women.31
1.5 All patients with a history of fragility fracture should 
be offered BMD measurement and considered for 
treatment irrespective of the OSTA values because 
prior fracture predicts a very high risk of future 
fracture.32
Table 5. Recommended actions based on osteoporosis risk by the Osteoporosis Self-assessment Tool for Asians29
Osteoporosis risk Recommended actions
High risk Measure bone mineral density
Intermediate risk Measure bone mineral density if other risk factors are present
Low risk Bone mineral density measurement probably not necessary unless significant risk factors are present
FIG 2.  The Osteoporosis Self-assessment Tool for Asians29
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(E) Assessment of Fracture Risk
1. Clinical use of bone mineral density to assess fracture 
risk
1.1 Conventionally, BMD evaluation has been the 
primary focus for risk assessment.
1.2 BMD measurements with DXA at the lumbar spine 
and proximal femur give the best relative risk 
prediction for future fracture at the corresponding 
sites. In general, the relative risk of fracture 
increases by 1.5-3.0 times for each SD decrease in 
BMD.12,16
1.3 However, prospective population cohort studies 
have shown that most hip fractures (>50%) 
occurred in subjects without a BMD diagnosis of 
osteoporosis at baseline,33,34 such that BMD has a 
low sensitivity for fracture prediction.
1.4 Development of a new risk assessment tool, 
combining BMD and clinical risk factors, should 
enable more sensitive fracture risk prediction (refer 
to Section E3: The WHO Fracture Risk Assessment 
Tool on this page).
2. Clinical use of bone turnover markers to assess 
fracture risk
2.1 Population studies have shown that higher levels 
of bone formation and resorption markers were 
associated with significantly faster and greater 
bone loss. These markers may have the potential 
to help clinicians to identify fast bone losers for 
prompt intervention.26,27
2.2 Large prospective studies have shown that increases 
in biochemical markers of bone resorption, but not 
BFMs, are consistently associated with increases 
in risk of vertebral and non-vertebral fractures 
independent of BMD.26,27
2.3 Combining the measurements of BMD and 
markers of bone resorption may further refine the 
assessment of fracture risk.35
3. The WHO Fracture Risk Assessment Tool (FRAX®)
3.1 Facture risk is age-, gender- and country-specific, 
and is dependent on BMD, body mass index, and 
other clinical risk factors.
3.2 Those clinical risk factors, which have been 
identified to be independent fracture risk 
predictors, include age, low body weight, prior 
fragility fracture, a parental history of hip fracture, 
smoking, use of systemic corticosteroids, excess 
alcohol consumption, and rheumatoid arthritis.36
3.3 In 2008, the WHO successfully launched the WHO 
Fracture Risk Assessment Tool (FRAX®), which 
is a simple ethnic-specific web-based tool that 
integrates clinical information in a quantitative 
manner to predict a 10-year probability of major 
osteoporotic fracture and hip fracture for both 
women and men (http://www.shef.ac.uk/FRAX/).37
3.4 FRAX is a practical tool derived from a series 
of meta-analyses using the primary data from 
population-based cohorts that have identified a 
number of clinical risk factors for fracture. The 
performance characteristics of clinical risk factors 
have been validated in independent, population-
based, prospectively studied cohorts with over 1 
million person-years of observation.38
3.5 Computation of the 10-year fracture probability 
would help to guide individual treatment decisions. 
The level of absolute fracture probability above 
which pharmacological treatment is indicated 
depends on the availability of health care resources 
and priority of the health care system for treatment 
of osteoporosis.
3.6 The US National Osteoporosis Foundation (NOF) 
recommends treatment if the 10-year probability of 
a major osteoporotic fracture is ≥20% or the 10-year 
probability of a hip fracture is ≥3% based on the 
US-adapted WHO algorithm.39 This recommended 
treatment threshold has been proven to be cost-
effective in a US economic model.40
3.7 A Hong Kong population–specific FRAX algorithm 
has become available, which is based on a 
prospective follow-up study of 1435 treatment-naïve 
community-dwelling, postmenopausal, southern 
Chinese women for incident osteoporotic fracture, 
and the 10-year risk of osteoporotic fracture was 
predicted from the risk factor assessment and BMD 
measurement.41
3.8 It must be cautioned that FRAX only applies to 
postmenopausal women or men aged 50 years 
or older who have not been treated. FRAX does 
not apply to pre-menopausal women, younger 
adults, or children. FRAX has not accommodated 
other known clinical risk factors such as fall and 
biochemical markers. Overall, FRAX does not 
replace clinical judgement. The decision to treat 
must still be made on an individual case-by-case 
basis.
(F) Clinical Assessment of Osteoporosis
1.1 A comprehensive approach to all patients with 
osteoporosis is recommended.
1.2 A detailed history and physical examination should 
be obtained. Central DXA BMD assessment should 
preferably be performed as a baseline. Vertebral 
fracture assessment may be obtained at the time 
of DXA measurements, if available. Otherwise, 
X-rays of the thoracic and lumbar spine should be 
performed if vertebral fracture is suspected.
1.3 The Hong Kong population–specific FRAX 10-year 
fracture probability is useful to establish an 
individual patient’s fracture risk, especially for 
those with BMD in the osteopenic range.
1.4 One of the main objectives of a detailed 
assessment is to exclude underlying secondary 
causes of osteoporosis (Table 4). This is particularly 
relevant for male subjects because a Caucasian 
study suggested that >50% of men presenting with 
symptomatic vertebral fracture had an underlying 
secondary cause.42
1.5 Basic laboratory investigations should include 
complete blood count, erythrocyte sedimentation 
rate, liver and renal function tests (including 
alkaline phosphatase, serum calcium and 
phosphate), thyroid function, and a 24-hour urine 
test for calcium excretion. Testosterone level 
should be considered in men.
1.6 Additional special tests such as serum protein 
electrophoresis, parathyroid hormone (PTH), 
25-hydroxyvitamin D (25OHD) and cortisol level 
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may be considered if the history and initial workup 
suggest a related disorder. Specific bone marker 
tests may be considered, if available.
(G) Non-pharmacological Management of 
Osteoporosis
1. Lifestyle measures
1.1 Lifestyle measures remain the basic universal 
recommendation to the general population for 
prevention and non-pharmacological management 
of osteoporosis. A ‘population approach’ targeting 
adolescents before their accretion of peak bone 
mass is especially important to reduce the burden 
of the disease in the community.
1.2 Lifestyle measures include consumption of a 
healthy balanced diet rich in calcium and vitamin D, 
regular weight-bearing and muscle-strengthening 
exercises, avoidance of smoking and excessive 
alcohol intake, and adequate sunlight exposure.
2. Calcium
2.1 Importance of calcium
    2.1.1 Adequate calcium intake is important to 
optimise bone health.
    2.1.2 A meta-analysis of 23 randomised trials 
involving 41 419 adults aged 50 years or 
older confirmed that adequate calcium 
supplementation, with or without vitamin D, 
was associated with significantly reduced rates 
of bone loss of 0.54% at the hip and 1.19% in 
the spine.43
    2.1.3 The same article also reported another meta-
analysis of 17 randomised trials involving 
52 625 adults aged 50 years or older with 
fracture as an outcome measure showed that 
adequate calcium supplementation, with 
or without vitamin D, was associated with a 
significant 12% risk reduction of fractures of 
all types. The treatment effects were greatest 
with calcium doses of ≥1200 mg and with 
vitamin D doses of ≥800 IU daily.43
    2.1.4 After a comprehensive review of all the 
available evidence, the Institute of Medicine 
(IOM) of the US National Academy of Sciences 
stated in its 2011 report that the recommended 
dietary allowance (RDA) for calcium was 
1000 mg daily for adults of both sexes and a 
higher 1200 mg daily for women older than 50 
years and men older than 70 years.44 The RDA 
reflects the estimated requirement for 97.5% 
of the general healthy population.
    2.1.5 According to early reports from the 1980s and 
1990s, a traditional Chinese diet contained a 
much lower calcium content of around 400 mg 
daily.45,46 Publications from the 2000s showed 
an increase in daily dietary calcium content to 
around 500-600 mg.47,48
    2.1.6 Dairy products are the major food source of 
calcium. The calcium content of some common 
local food is listed in Table 6. However, about 
50-100% of Asians have lactose intolerance.49 
Lactose-intolerant individuals are at risk of 
calcium inadequacy.
    2.1.7 Calcium supplementation should be 
considered for patients who cannot obtain 
sufficient calcium from food, especially those 
with lactose intolerance.
    2.1.8 Calcium supplementation should preferably 
be in the form of calcium carbonate or 
calcium citrate for better bioavailability and 
absorption. Calcium supplementation should 
be taken with food as gastric acidity promotes 
absorption.
2.2 Cautions for calcium supplementation
    2.2.1 Common adverse effects of calcium 
supplementation are dyspepsia and 
constipation, which may settle with increasing 
fluid intake or dietary fibre consumption. 
Otherwise, another type or brand of calcium 
supplement may be tried.
    2.2.2 The IOM has set the upper level of calcium 
intake at 2000 mg daily for adults older than 
50 years to avoid harmful effects, notably renal 
stones.44
    2.2.3 There have been some recent reports 
suggesting a potential link between the use of 
calcium supplementation and an increase in 
cardiovascular risk.
 2.2.3.1 A meta-analysis of 11 randomised 
controlled trials (RCTs) involving 11 921 
subjects with a mean follow-up of 4.0 
years reported a 30% increase in risk of 
myocardial infarction (MI) in subjects 
receiving calcium supplement ≥500 mg 
daily without co-administered vitamin D.50
 2.2.3.2 In the European Prospective Investigation 
into Cancer and Nutrition (EPIC) study 
involving 25 540 German residents 
aged 35-64 years, users of calcium 
supplementation had a significant 86% 
increase in MI risk compared with non-
users after an average follow-up of 11 
years. However, increased calcium intake 
from the diet did not confer significant 
cardiovascular benefit or risk.51
    2.2.4 These data may suggest a potential detrimental 
effect of calcium supplementation on 
cardiovascular health. The NOF, in a recent 
publication, stated that the bone health 
benefits of calcium intake are extensively 
documented in the scientific literature 
and more research is needed before any 
conclusions can be drawn.52
2.3 Proton pump inhibitors and calcium
    2.3.1 Many observational studies have reported an 
association between the use of proton pump 
inhibitors (PPIs) and a modest increase in risk 
Table 6. Calcium content of some common local foods
Food item Calcium content (mg per 100 g)
Cheese 675
Sardine 400
Bean curd sheet 330
Almond 250
Yogurt 170
Tofu 150
Milk 120
Broccoli 75
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of fractures, possibly mediated through an 
effect of inhibition of gastric acid secretion on 
calcium absorption and BMD.53
    2.3.2 Two recent meta-analyses have suggested 
that the risk of fracture was increased by 
10-40% above baseline in subjects receiving 
PPIs, especially when they were used at high 
doses and over long durations (>1 year), but 
not in patients taking histamine 2-receptor 
antagonists.54,55
    2.3.3 Patients who require continuous PPI therapy 
should be strongly encouraged to ensure that 
they receive the recommended daily intake of 
calcium and vitamin D.
2.4 Recommendations for calcium intake
    2.4.1 A daily elemental calcium intake of 1000-1200 
mg should be recommended for osteoporosis 
patients if there are no contra-indications; the 
total amount of calcium should not exceed 
2000 mg daily.
    2.4.2 Individuals should preferably meet their daily 
calcium requirement from dietary sources. 
Calcium supplementation is indicated for 
those with a low dietary calcium intake and 
who are unable to achieve the recommended 
level through dietary sources.
    2.4.3 Patients who require continuous PPI therapy 
should be strongly encouraged to ensure that 
they receive the recommended daily intake of 
calcium and vitamin D.
3. Vitamin D
3.1 Importance of vitamin D
    3.1.1 Vitamin D is essential for promoting calcium 
absorption in the gut and maintaining adequate 
serum calcium and phosphate concentrations 
to enable normal mineralisation of bone. In 
addition, vitamin D plays an important role in 
neuromuscular function.
    3.1.2 Vitamin D inadequacy results in increased PTH 
secretion (secondary hyperparathyroidism), 
which in turn accelerates bone resorption, 
notably from cortical sites.
    3.1.3 Optimal serum 25OHD concentration is 
considered to be the level that is associated 
with maximal PTH suppression. Estimates 
of that threshold level have been found to 
be clustered around 68-75 nmol/L (27.2-30.0 
ng/mL).56
    3.1.4 The conversion factor for vitamin D is 1 ng/mL 
= 2.5 nmol/L.
    3.1.5 Vitamin D deficiency occurs when the serum 
level of 25OHD falls below 25 nmol/L (10 
ng/mL) resulting in rickets in children or 
osteomalacia in adults. However, there have 
been ongoing debates regarding the levels of 
25OHD that are considered to be ‘optimal’ for 
bone health.
    3.1.6 Previous studies and meta-analyses have been 
inconsistent in accurately defining the efficacy 
of vitamin D supplementation in fracture 
prevention. The discordant findings may be 
explained, in part, by the differences in the 
criteria for including trials in the analyses, with 
respect to blinding, vitamin D formulation 
(oral vs injectable) or accommodations for 
non-adherence.
    3.1.7 A recent meta-analysis employing pooled 
participant-level data (ie according to the actual 
intake of each participant) from 11 double-
blind, RCTs of oral vitamin D supplementation 
(daily, weekly, or every 4 months), with or 
without calcium, compared with placebo or 
calcium alone in 31 022 subjects aged 65 years 
or older showed that reduction in fracture 
risk was only evident at the highest quartile 
of actual vitamin D intake (792-2000 IU daily) 
with a significant 30% reduction in the risk of 
hip fracture and a significant 14% reduction in 
the risk of any non-vertebral fracture. Benefits 
at the highest level of vitamin D intake were 
fairly consistent across subgroups defined by 
age-group, type of dwelling, baseline 25OHD 
level, and additional calcium intake.57
    3.1.8 Regarding the effect of vitamin D on 
fall prevention, a meta-analysis of eight 
randomised trials involving 2426 elderly 
subjects with a mean age of 65 years or older 
showed that high-dose supplemental vitamin 
D (700-1000 IU daily) significantly reduced fall 
risk by 19%, whereas achieved serum 25OHD 
concentrations of ≥60 nmol/L (≥24 ng/mL) 
resulted in a significant 23% fall reduction. 
Falls were not notably reduced by low-dose 
supplemental vitamin D (200-600 IU daily) or 
by achieved serum 25OHD concentrations of 
<60 nmol/L.58
    3.1.9 The potential non-skeletal health benefits 
of vitamin D59 are beyond the scope of the 
current guideline.
    3.1.10 The 2010 IOM report recommended that the 
RDA for vitamin D was 600 IU daily for adults 
and a higher 800 IU daily for elderly (>70 
years), corresponding to a serum 25OHD level 
of ≥50 nmol/L.44 These recommendations are 
intended to meet the requirement of 97.5% of 
the healthy general population.
    3.1.11 The NOF, the International Osteoporosis 
Foundation (IOF), and the US Endocrine 
Society all recommended a higher 25OHD 
level of 75 nmol/L (30 ng/mL) to be the desired 
target for fracture and fall prevention.39,60,61 
The estimated mean vitamin D requirement 
to reach this target 25OHD level is 800-1000 
IU/day. A considerably higher dose (up to 2000 
IU/day) may be required for individuals who 
are obese, and for those with osteoporosis, 
limited sun exposure (institutionalised, 
homebound) or malabsorption, and for 
certain ethnic populations known to be at 
high risk for vitamin D deficiency (those from 
the Middle East and South Asia).60
    3.1.12 Synthesis of cholecalciferol (vitamin D3) from 
its precursors in the skin under the effect of 
ultraviolet light of wavelength 290-315 nm 
constitutes a major source of vitamin D. 
Around 10-15 minutes of sunlight exposure 
every day to the exposed areas over the face, 
hands, and arms is considered adequate 
		#		The	Osteoporosis	Society	of	Hong	Kong	#
14	 Hong	Kong	Med	J		Vol	19	No	2	#	Supplement	2	#		April	2013
to meet the daily requirement of vitamin 
D in young adults. The effect of ageing can 
decrease the ability of the skin to synthesise 
vitamin D by more than 2-fold in elderly 
people.62
3.2 Issue of vitamin D inadequacy
    3.2.1 Vitamin D inadequacy is more prevalent in 
the elderly population due to less efficient 
synthesis of vitamin D3 in the skin, decreased 
renal production of 1,25-dihydroxyvitamin 
D (1,25OHD), less efficient absorption of 
calcium in the gastro-intestinal tract and re-
absorption in the kidney tubules.
    3.2.2 Using a cut-off value of 75 nmol/L, the 
prevalence of vitamin D inadequacy has 
been reported to be >50% in community-
dwelling postmenopausal women across all 
geographical regions of the world, with Asia 
having a prevalence of 71.4%.63
    3.2.3 A local study also showed that vitamin 
D inadequacy was present in >60% of 
community-dwelling adults older than 
50 years.64 Lack of outdoor activities and 
preference for avoiding sunlight exposure 
have been demonstrated among local middle-
aged and elderly women.65
    3.2.4 Local studies have confirmed genuine vitamin 
D inadequacy in high-risk groups, notably 
hospitalised patients with hip fracture.66,67
3.3 Vitamin D supplementation
    3.3.1 Vitamin D is relatively scarce in food. The chief 
dietary sources of vitamin D are saltwater fish 
(ie salmon, tuna, and mackerel), fish liver oil, 
liver, egg yolks, and vitamin D-fortified milk or 
cereal products.
     3.3.2 Vitamin D supplements are available as 
ergocalciferol (vitamin D2) or cholecalciferol 
(vitamin D3) in strengths up to 50 000 IU per 
tablet.
    3.3.3 With daily dosing, vitamin D2 appears to 
be as effective as vitamin D3 in maintaining 
circulating concentrations of 25OHD,68 but 
with intermittent (weekly or monthly) dosing, 
vitamin D3 appears to be about 3 times more 
potent than vitamin D2.69 On average, each 
100 IU of added vitamin D3 will increase the 
serum 25OHD level by about 2.5 nmol/L or 1.0 
ng/mL.70
    3.3.4 The margin of safety for prescription of a 
vitamin D supplement is considerably wide. 
A serum 25OHD concentration consistently 
>500 nmol/L is considered toxic. Studies 
have shown that a daily vitamin D dose of 
10 000 IU could only achieve serum 25OHD 
concentrations of <140 nmol/L. Daily vitamin 
D intake of >40 000 IU is required to achieve a 
toxic level of >500 nmol/L.71
    3.3.5 The 2010 IOM report has set the upper level of 
vitamin D intake to be 4000 IU daily.44
    3.3.6 Patients in all the landmark clinical trials 
of anti-osteoporosis medications had 
received calcium, with or without vitamin 
D, supplementation. There is evidence that 
calcium and vitamin D could enhance the 
antiresorptive and anti-fracture efficacy of 
bisphosphonates.72,73 A recent observational 
study showed that a mean 25OHD level of ≥33 
ng/mL (≥82.5 mmol/L) was needed to maintain 
a favourable bisphosphonate response.74
    3.3.7 A recent RCT involving 2256 community-
dwelling elderly women aged 70 or older 
showed that annual oral administration of 
high-dose (500 000 IU) vitamin D3 resulted in 
increased risk of falls and fracture, especially 
during the first 3 months after dosing.75 It 
was proposed that the high oral dose may 
have triggered a short-term ‘protective’ 
upregulation of the enzyme responsible for 
degrading 1,25OHD, resulting in decreased 
blood and tissue levels of 1,25OHD, leading to 
falls.76
3.4 Recommendations for vitamin D supplementation
    3.4.1 Vitamin D supplementation should be given 
whenever anti-osteoporosis medications are 
started unless there are contra-indications.
    3.4.2 An average vitamin D intake of ≥800 IU daily is 
recommended; a higher dose is required for 
certain subgroups of patients who are at risk of 
vitamin D inadequacy. There is ample evidence 
that a high vitamin D intake is necessary to 
enhance the anti-fracture efficacy of most 
anti-osteoporosis medications, especially the 
bisphosphonates.
    3.4.3 The upper level of vitamin D intake is set at 
4000 IU daily.
    3.4.4 Vitamin D supplementation can be given as a 
daily, weekly, or monthly oral dose of either 
vitamin D2 or D3, but should not be given as 
an annual oral high dose.
    3.4.5 Contra-indications include recurrent 
urolithiasis and untreated diseases of 
bone and mineral metabolism such as 
hyperparathyroidism and metastatic bone 
diseases.
4. Active vitamin D analogues
4.1 Active vitamin D analogues are hydroxylated 
metabolites of vitamin D, and they increase intestinal 
calcium absorption pharmacologically. Examples 
include 1α-hydroxyvitamin D3 (alphacalcidol) and 
1,25-dihydroxyvitamin D3 (calcitriol).
4.2 In a meta-analysis involving two RCTs, active vitamin 
D analogues reduced the risk of fall by 22%.77 These 
analogues probably reduced vertebral fracture, 
whereas their effect on reducing non-vertebral 
fracture was uncertain.77
4.3 A meta-analysis showed that hypercalcaemia 
was significantly increased by 4.4-fold in patients 
receiving calcitriol.78
4.4 These analogues have a relatively low margin of 
safety, with potential risks for hypercalcaemia 
and hypercalciuria. Generally, they are not 
recommended for use as vitamin D supplementation 
in otherwise healthy postmenopausal women.
5. Exercise
5.1 Exercise plays an important role in achieving peak 
bone mass and building and maintaining bone 
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strength. Exercise also modestly helps to reduce 
bone loss in elderly people.79
5.2 In addition to its effect on bone strength, exercise 
also helps to build muscle mass and maintain 
muscle strength.
5.3 Weight-bearing, muscle strengthening, and 
balance-training exercises are particularly useful to 
improve agility, strength, posture, coordination and 
balance, and reduce the risk of fall.
5.4 Immobilisation or inactivity, on the other hand, 
accelerates bone loss and should be avoided for 
elderly people as far as possible. Worries about 
falling should not be a reason of physical inactivity.
5.5 Weight-bearing exercises include brisk walking, 
jogging, Tai Chi, dancing, and stair-climbing. 
High-impact weight-bearing exercises are not 
recommended for elderly people as many of them 
have concomitant osteoarthritis.
5.6 Tai Chi is a form of low-impact weight-bearing 
exercise, and has been shown in the western 
literature to improve balance and reduce the 
incidence of fall and fall-related injuries.80,81 A more 
detailed discussion of Tai Chi is available in Section 
G6 (Tai Chi exercise on this page).
5.7 Muscle-strengthening exercises include weight 
training and other isometric resistance exercises.
5.8 Structured exercise programme for osteoporotic 
subjects should specifically target on posture, 
balance, gait, coordination, and hip and trunk 
stabilisation.
5.9 Exercise should be recommended for all age-
groups not only for osteoporosis prevention and 
treatment but also for overall health benefits.
6. Tai Chi exercise
6.1 Tai Chi Chuan is a traditional Chinese martial art, 
with a history of over 300 years from the late Ming 
Dynasty.
6.2 Tai Chi is a unique form of low-impact exercise that 
requires high neuromuscular coordination and 
specific training in low-velocity muscle contraction. 
6.3 Local small-scale studies have shown that short-
term training with Tai Chi exercise improved 
cardiopulmonary fitness,82 trunk flexibility,82 lower 
limb muscle strength,82,83 muscle endurance,83 
coordination,84,85 and balance85,86 among the elderly.
6.4 A prospective, RCT in the US showed that 15 weeks’ 
training with Tai Chi resulted in a significant 47.5% 
reduction in the risk of multiple falls among 200 
community-dwelling elderly aged 70 years or older, 
with significant concomitant improvements in 
measures of fear of falling.81
6.5 The effect of Tai Chi on BMD was demonstrated in 
a RCT in which Tai Chi training (45 minutes a day, 5 
days a week for 12 months) in 132 postmenopausal 
women with a mean age of 54 years significantly 
retarded the rate of both cortical and trabecular 
bone loss in the weight-bearing bones as measured 
by pQCT.87
6.6 A meta-analysis involving 47 studies showed that 
benefits of Tai Chi were reported in balance and 
strength, cardiovascular and respiratory function, 
flexibility, the immune system, symptoms of 
arthritis, muscular strength, and psychological 
effects.80
6.7 Tai Chi is strongly recommended as an appropriate 
and safe exercise for older adults for general health 
and fall prevention.
(H) Pharmacological Treatment of 
Osteoporosis
1. General considerations
1.1 The ultimate goal of pharmacological treatment 
is to reduce fracture risk, increase survival, and 
improve quality of life.
1.2 Anti-osteoporosis medications can be broadly 
classified into antiresorptive, bone-forming 
(anabolic), and uncoupling agents (Table 7). 
Antiresorptive agents act mainly on osteoclasts by 
reducing the rate of bone resorption and bone 
remodelling. Bone-forming agents act mainly 
on osteoblasts by directly stimulating new bone 
formation. Uncoupling agent appears to dissociate 
bone remodelling to increase bone formation and 
decrease bone resorption.
1.3 The locally available anti-osteoporosis medications 
* Approved either by the United States Food and Drug Administration or the European Medicines Agency 
† Post-hoc analysis in high-risk subgroups
Table 7. Pharmacological treatment options for postmenopausal osteoporosis: indications and anti-fracture 
efficacy of individual anti-osteoporosis agents (evidence from individual randomised placebo-controlled treatment 
trials)88,89,101,110,116-118,125-127,136,143,144,150,161,162,176
Age-group (years) Approved indications* Documented fracture reduction
Prevention Treatment Vertebral Non-vertebral Hip
Antiresorptive agents
Hormone replacement therapy + - + + +
Raloxifene + + + - -
Calcitonin - + + - -
Alendronate + + + + +
Risedronate + + + + +
Ibandronate + + + +† -
Zoledronic acid + + + + +
Denosumab + + + + +
Anabolic agent
Teriparatide - + + + -
Uncoupling agent
Strontium ranelate - + + + +†
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that have been approved by the US Food and 
Drug Administration (FDA) for treatment and/
or prevention of postmenopausal osteoporosis 
include HRT, calcitonin, bisphosphonates 
(including alendronate, risedronate, ibandronate, 
and zoledronic acid), raloxifene, teriparatide, and 
denosumab. In addition, the European Medicines 
Agency (EMA) has also approved the use of 
strontium ranelate.
1.4 Phytoestrogens and tibolone are other agents that 
have aroused interest in this field, but there is 
insufficient clinical evidence for phytoestrogens 
and there are potential safety concerns with 
tibolone, so these drugs have not been approved 
for treatment of postmenopausal osteoporosis.
1.5 Since there is a lack of direct head-to-head 
comparison studies with fracture as the primary 
endpoint, the most effective treatment for 
osteoporosis has yet to be determined.
2. Hormone replacement therapy 
2.1 Estrogen suppresses osteoclastic bone resorption, 
reduces bone turnover to the premenopausal state, 
and maintains a positive calcium balance through 
its effect on the intestine and kidneys.
2.2 The beneficial effects of estrogen on bone mass 
and fracture risk reduction have clearly been 
demonstrated in large prospective, double-blind, 
RCTs. The Women’s Health Initiative (WHI) study, 
involving 27 347 postmenopausal women with a 
mean age of 63 years, confirmed that estrogen-only 
therapy (ET) or combined estrogen-progestogen 
therapy (EPT) reduced the risk of hip fracture by 
33-39% and the risk of any fracture by 24%.88,89
2.3 However, the significant increase in incidences 
of breast cancer, stroke, heart attack, and venous 
thromboembolism (VTE) in the EPT arm and the 
significant increase in the incidence of stroke in 
the ET arm outweighed the benefit of fracture 
risk reduction in this group of relatively older 
postmenopausal women.88,89
2.4 Secondary analysis of the WHI data, however, 
supports the initiation of HRT around the 
time of menopause. ET was shown to have a 
reduced coronary artery disease risk (coronary 
revascularisation, MI, and coronary death) 
when initiated in younger and more recently 
postmenopausal hysterectomised women.90
2.5 ET was also demonstrated to offer no increase in 
risk of breast cancer after an average of 7.1 years of 
use regardless of the age at initiation of therapy.91
2.6 The latest 2012 North American Menopause 
Society (NAMS) Position Statement supported the 
initiation of HRT around the time of menopause to 
treat menopause-related symptoms and to prevent 
osteoporosis in women at high risk for fracture. The 
report stated that the benefit-risk ratio is especially 
favourable for ET in hysterectomised women in 
whom the duration of use can be flexibly extended 
up to 7 years, whereas the earlier appearance of 
increased breast cancer risk for EPT precludes a 
recommendation for its use beyond 3-5 years.92
2.7 The US Endocrine Society Scientific Statement also 
supported the start of HRT in the subgroups of 
women aged between 50 and 59 years or those less 
than 10 years after onset of menopause because 
congruent trends suggested additional benefits, 
including reduction of overall mortality and 
coronary artery disease.93
2.8 The safety of HRT in recently postmenopausal 
women was supported by two recently published 
RCTs.
    2.8.1 The Danish Osteoporosis Prevention Study, 
involving 1006 women aged 45-58 years with 
a mean of 7 months postmenopause, showed 
that after 10 years of randomised treatment, 
women receiving HRT early after menopause 
had a significantly reduced risk of mortality, 
MI or heart failure, without any apparent 
increase in risk of cancer, VTE or stroke.94
    2.8.2 The Kronos Early Estrogen Prevention Study 
(KEEPS), involving 727 US women aged 42-58 
years within 3 years of menopause, showed 
that after 4 years of randomised treatment, 
there were no significant differences in 
adverse events (breast cancer, endometrial 
cancer, MI, transient ischaemic attack, 
stroke, or VTE) between the HRT and placebo 
groups.95
2.9 Recommendations: Current evidence supports the 
use of HRT (notably ET for hysterectomised women) 
as an option for young postmenopausal women 
(age 50-59 years or <10 years postmenopause) 
for prevention and treatment of osteoporosis, 
especially for those with climacteric symptoms. 
Patients need to be adequately counselled on the 
risks and benefits of long-term use, beyond 3-5 
years for EPT and beyond 7 years for ET. Contra-
indications include a history of VTE or breast 
cancer.
3. Phytoestrogens
3.1 Phytoestrogens are natural chemicals found in 
plants. Animal studies have demonstrated that 
phytoestrogens have a protective effect against 
estrogen-related bone loss.
3.2 The two main classes of phytoestrogens that are 
of medical interest are isoflavones and lignans. 
Isoflavones are found in beans and soya products, 
eg soya milk and tofu. Lignans are found in ryes, 
berries, fruits, vegetables, and whole grains.
3.3 Extracted phytoestrogens have been marketed as 
dietary supplements.
3.4 Local cross-sectional and prospective studies have 
shown that phytoestrogens had positive effects 
on BMD and bone markers in postmenopausal 
women.96-98
3.5 There is no clinical up-to-date evidence that 
phytoestrogens in any form reduce the risk of any 
osteoporotic fracture in prospective clinical trials.99
4. Tibolone
4.1 Tibolone is a synthetic steroid, and its metabolites 
have estrogenic, progestogenic, and androgenic 
activities.
4.2 Tibolone has been shown to prevent bone loss 
both in animal and in human studies.
4.3 Tibolone has been licensed in more than 90 
countries for treatment of climacteric symptoms.
4.4 In the Long-term Intervention on Fractures 
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with Tibolone study (LIFT), tibolone given to 
postmenopausal women at a dose of 1.25 mg daily 
significantly reduced the risks of vertebral fracture 
by 45% and of non-vertebral fracture by 26% over 
34 months. However, a significant 2.2-fold increase 
in the risk of stroke necessitated premature 
termination of the study.100
4.5 Despite its anti-fracture efficacy, tibolone has not 
been approved by the FDA for long-term treatment 
of osteoporosis, and it definitely should not be 
recommended for elderly women or for women 
with risk factors for stroke.
5. Selective estrogen receptor modulators
5.1 Selective estrogen receptor modulators (SERMs) 
are non-hormonal agents that bind with high 
affinity to the estrogen receptors, but with 
differential effects at different target tissues. They 
exhibit estrogen-agonistic effects on bone and 
estrogen-antagonistic effects on the endometrium 
and breast.
5.2 Raloxifene is the SERM currently available for 
prevention and treatment of postmenopausal 
osteoporosis in Hong Kong.
5.3 Efficacy
    5.3.1 In the Multiple Outcomes of Raloxifene 
Evaluation (MORE) study, treatment with 
raloxifene at a dose of 60 mg daily for 36 months 
increased spinal BMD by 2.6% and femoral 
neck BMD by 2.1% over placebo, and reduced 
bone turnover to premenopausal levels. The 
risk of vertebral fracture was significantly 
reduced by 30%, but the reduction in risk of 
non-vertebral fracture was insignificant.101
    5.3.2 An Asian study has also confirmed the 
efficacy of raloxifene in increasing BMD and 
suppressing biochemical BTMs in healthy 
Asian postmenopausal women.102
    5.3.3 The increase in BMD with raloxifene treatment 
is very modest, and only explains 4% of the 
vertebral fracture risk reduction associated 
with raloxifene treatment.103
5.4 Extra-skeletal benefits 
    5.4.1 Raloxifene reduced total cholesterol and low-
density lipoprotein cholesterol by about 6% 
and 10%, respectively.104
    5.4.2 Raloxifene reduced the risk of invasive breast 
cancer by approximately 70%.105,106
    5.4.3 Raloxifene has been approved by the FDA for 
chemoprevention of invasive breast cancer in 
high-risk women; its efficacy was reported in 
the 5-year Study of Tamoxifen and Raloxifene 
(STAR) trial to be comparable to tamoxifen, 
but with a lower risk of endometrial cancer.107
    5.4.4 An updated analysis with an 81-month median 
follow-up of the STAR trial participants 
confirmed the long-term efficacy of raloxifene 
in prevention of invasive breast cancer, but 
with much less toxicity than tamoxifen.108
5.5 Adverse effects: common minor adverse effects 
include hot flushes and leg cramps. Major 
complications include VTE.
5.6 Long-term data: 8-year long-term follow-up data 
showed that raloxifene was associated with a 1.7-
fold increase in incidence of VTE. There was no 
increase in the incidence of MI, stroke, uterine 
cancer, endometrial hyperplasia, ovarian cancer, or 
postmenopausal bleeding.109
5.7 Preparation: raloxifene is prescribed as a 60-mg 
tablet to be taken daily without regard to the timing 
of meals.
5.8 Recommendations: With the paucity of evidence 
for non-vertebral fracture risk reduction, raloxifene 
is recommended more preferably for use in 
younger postmenopausal women when the risk 
of hip fracture is not particularly high. Raloxifene 
may be safely administered in the long term, but a 
switch to more potent agents may be needed when 
the risk of hip fracture becomes higher as patients 
age.
6. Calcitonin
6.1 Calcitonin was approved by the FDA in 1995 for 
treatment of postmenopausal osteoporosis.
6.2 Calcitonin is a peptide hormone with antiresorptive 
properties on the osteoclasts. Calcitonin can be 
administered either by subcutaneous injection or 
as a nasal spray.
6.3 Efficacy
    6.3.1 In the 5-year Prevent Recurrence of 
Osteoporotic Fractures (PROOF) study, a 
significant 36% reduction in vertebral fracture 
risk was shown only in the group treated 
with intranasal calcitonin 200 IU daily. Risk 
reduction in non-vertebral fracture was not 
significant at any of the doses tested.110
    6.3.2 There are no data on the use of calcitonin for 
prevention of osteoporosis.
    6.3.3 Both subcutaneous and intranasal calcitonin 
have been shown to reduce pain and hasten 
remobilisation of patients after acute vertebral 
compression fractures.111,112
6.4 Adverse effects
    6.4.1 Common adverse effects include rhinitis, 
irritation of the nasal mucosa, epistaxis, and 
anaphylaxis reactions.
    6.4.2 After complete review of the benefits and 
risks of calcitonin-containing medications, the 
EMA, in July 2012, concluded that there was 
evidence of a small increase in risk of cancer 
of various types with its long-term use (2.4% 
for the intranasal formulation). The benefits 
of calcitonin did not outweigh the risks, 
so calcitonin should no longer be used for 
treatment of osteoporosis and the nasal spray 
formulation should be withdrawn from the 
market. Parenteral formulations of calcitonin 
should be limited to use at the smallest 
effective dose for the shortest possible time 
for three conditions: Paget’s disease, acute 
bone loss due to sudden immobilisation, and 
hypercalcaemia caused by cancer.113
6.5 Recommendations: Due to its inconsistent anti-
fracture efficacy, calcitonin is seldom used for long-
term treatment of osteoporosis. With the recent 
EMA warnings on the potential risk of cancer, 
calcitonin should no longer be used for treatment 
of osteoporosis.
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7. Bisphosphonates as a class
7.1 Bisphosphonates are currently considered to be 
the mainstay of pharmacological therapy for the 
prevention and treatment of osteoporosis in both 
postmenopausal women and elderly men.
7.2 Bisphosphonates bind tightly to the mineralised 
bone surface, where they are ingested by osteoclasts 
leading to apoptosis and loss of function of the 
osteoclasts. The rate of bone turnover is reduced 
and secondary mineralisation is enhanced.
7.3 Etidronate was the first-generation bisphosphonate, 
but continuous exposure to etidronate could 
cause mineralisation defects, so it is currently not 
recommended for osteoporosis management.
7.4 Currently approved bisphosphonates include 
alendronate, ibandronate, risedronate and 
zoledronic acid, all of which are nitrogen-containing 
derivatives that are 100-1000 times more potent 
than etidronate, and are effective in inhibiting bone 
resorption without causing mineralisation defects.
7.5 The potency and long duration of action of the 
currently approved bisphosphonates favour 
their intermittent use, and these compounds can 
be administered orally as a daily (alendronate, 
risedronate), weekly (alendronate, risedronate), 
or monthly (ibandronate, risedronate) dose, or 
intravenously at intervals of 3 months (ibandronate) 
or 12 months (zoledronic acid).
7.6 Infrequent oral dosing and intravenous 
preparations may help to improve adherence and 
acceptance of treatment.
7.7 Bisphosphonates are poorly absorbed from the 
gastro-intestinal tract (<1%) and oral preparations 
must be given with special instructions to ensure 
absorption and reduce adverse effects:
 (i) bisphosphonates must be taken after a 
prolonged fast (usually first thing in the 
morning) and should not be taken with meals 
or calcium tablets, and preferably not with 
other medications
 (ii) bisphosphonates must be taken with a full 
glass of water (≥250 mL)
 (iii) patients should remain upright (either sitting 
or standing) and take nothing else by mouth 
for ≥30 minutes
7.8 Common adverse effects include upper gastro-
intestinal effects and musculoskeletal pain. Upper 
gastro-intestinal adverse effects are a result of 
direct chemical irritation of the mucosa by the 
bisphosphonate and include epigastric discomfort, 
pain, flatulence, regurgitation, heartburn and, 
on rare occasions, oesophagitis, oesophageal 
erosion and ulceration. Musculoskeletal pain 
may be disabling and can occur during initial use 
of bisphosphonates, or even weeks or months 
afterwards.
7.9 The Cochrane Database of Systematic Reviews on 18 
RCTs involving more than 26 000 patients reassured 
that the incidence of upper gastro-intestinal 
adverse effects were similar between the treatment 
groups and placebo114,115 if the instructions for drug 
ingestion were followed correctly.
7.10 Contra-indications to oral bisphosphonates 
include hypersensitivity to bisphosphonates, 
hypocalcaemia, active peptic diseases, and 
oesophageal abnormalities such as reflux 
oesophagitis, oesophageal stricture or achalasia. 
Bisphosphonates should be used with caution 
in patients with renal impairment and are contra-
indicated in patients with creatinine clearance of 
<30 mL/min/1.73 m2.
8. Alendronate
8.1 Alendronate was the first bisphosphonate approved 
by the FDA in 1995 for prevention and treatment of 
osteoporosis in postmenopausal women.
8.2 Efficacy
    8.2.1 Large-scale prospective RCTs have shown that 
alendronate increased BMD at the spine by 
6-9% and at the hip by 3-6% at 36 months.116-118
    8.2.2 Local studies have shown a comparable 
increase in BMD of 5-6% at the lumbar spine 
and 3-4% at the hip after 1 year of treatment 
with alendronate in postmenopausal 
osteoporotic Chinese women.119,120
    8.2.3 The 2008 Cochrane Database of Systematic 
Reviews on 11 RCTs involving 12 068 
postmenopausal women, showed that 
alendronate significantly reduced the relative 
risk of vertebral fracture by 45% both for 
primary and secondary prevention, reduced 
non-vertebral fracture by 23% for secondary 
prevention, and reduced hip fracture by 53% 
for secondary prevention.114
    8.2.4 Alendronate has also been shown to be 
effective in increasing BMD and prevention 
of vertebral fracture in men121 and in subjects 
with glucocorticoid-induced osteoporosis.122
8.3 Long-term data: Long-term follow-up data have 
confirmed that the anti-fracture efficacy of 
alendronate was maintained for up to 10 years with 
a good tolerability and safety profile.123
8.4 Preparations: Alendronate is available either as 
an oral daily dose of 10 mg or a weekly dose of 70 
mg.124 Weekly combination tablets with vitamin D3 
2800 or 5600 IU are available.
8.5 Recommendations: With its proven efficacy in 
reduction of vertebral, non-vertebral and hip 
fractures, alendronate is recommended as one of 
the first-line drugs for treatment of postmenopausal 
osteoporosis unless specifically contra-indicated 
(refer to Section H7.10 on this page).
9. Risedronate
9.1 Risedronate was the second bisphosphonate 
approved by the FDA in 2000 for prevention and 
treatment of osteoporosis in postmenopausal 
women. 
9.2 Efficacy
    9.2.1 The Vertebral Efficacy with Risedronate 
Therapy (VERT) studies125,126 and the Hip 
Intervention Program (HIP) study127 showed 
that risedronate significantly increased BMD 
at the spine by 5-6% and at the hip by 2-5% at 
36 months.
    9.2.2 A local study showed a comparable increase 
in BMD of 6.6% at the lumbar spine and 
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2.7% at the total hip after 1-year treatment of 
risedronate in postmenopausal osteoporotic 
Chinese women.128
    9.2.3 The 2008 Cochrane Database of Systematic 
Reviews on seven RCTs involving 14 049 
postmenopausal women, showed that 
risedronate significantly reduced the relative 
risk of vertebral fracture by 39%, that of 
non-vertebral fracture by 20% and that 
of hip fracture by 26%, all for secondary 
prevention.115
    9.2.4 Pooled analyses revealed that risedronate 
significantly reduced clinical vertebral and 
non-vertebral fractures as early as 6 months 
after treatment.129,130
    9.2.5 A subgroup analysis among very elderly 
osteoporotic women (age ≥80 years) showed 
a significant 81% risk reduction of vertebral 
fracture at 1 year and a 44% risk reduction at 
3 years; the numbers needed to treat (NNTs) 
were 12 and 16, respectively. However, the risk 
reduction of non-vertebral fracture was not 
significant.131
    9.2.6 A recent report confirmed the risk reduction 
of both vertebral and non-vertebral fractures 
in male osteoporotic subjects treated with 
risedronate for 2 years.132
    9.2.7 Risedronate has also been shown to improve 
BMD and reduce the incidence of vertebral 
fracture in glucocorticoid-treated subjects.133
9.3 Long-term data: Long-term follow-up data have 
confirmed that the anti-fracture efficacy of 
risedronate was maintained for up to 7 years with a 
good tolerability and safety profile.134
9.4 Preparations: Risedronate is available either as an 
oral daily dose of 5 mg or a weekly dose of 35 mg. A 
monthly oral dose of 150 mg has recently become 
available, which has demonstrated similar efficacy 
and safety to the standard daily dose.135
9.5 Recommendations: With its proven efficacy in 
reduction of vertebral, non-vertebral and hip 
fractures, risedronate is recommended as one of 
the first-line drugs for treatment of postmenopausal 
osteoporosis unless specifically contra-indicated 
(refer to Section H7.10 on page 18).
10. Ibandronate
10.1 Ibandronate is a potent, nitrogen-containing 
bisphosphonate with antiresorptive potency 1000- 
to 10 000-fold that of etidronate.
10.2 This potency, combined with favourable tolerability 
and bone-binding characteristics, allows 
ibandronate to be effectively administered less 
frequently than weekly.
10.3 Efficacy
    10.3.1 The Oral Ibandronate Osteoporosis Vertebral 
Fracture Trial in North America and Europe 
(BONE) showed that treatment with oral 
ibandronate at a daily dose of 2.5 mg for 3 
years in postmenopausal women significantly 
reduced the risk of morphometric vertebral 
fracture by 62%, concomitant with a significant 
6.5% improvement in spinal BMD and a 3.4% 
improvement in total hip BMD. However, 
a significant 69% reduction in risk of non-
vertebral fracture was only seen in a post-hoc 
analysis of a high-risk subgroup of subjects 
with a femoral neck BMD T-score of < –3.01.136
    10.3.2 The subsequent 2-year Monthly Oral 
Ibandronate In Ladies (MOBILE) study 
demonstrated that once-monthly oral 
ibandronate at a dose of 150 mg is at least 
as effective as the daily regimen in terms of 
efficacy in BMD improvement and safety 
profile.137
    10.3.3 In the head-to-head comparison Monthly Oral 
Therapy with Ibandronate for Osteoporosis 
Intervention (MOTION) study, once-monthly 
ibandronate 150 mg was shown to be clinically 
comparable with weekly alendronate 70 mg at 
increasing BMDs in both the lumbar spine and 
total hip after 12 months.138
    10.3.4 The Dosing Intravenous Administration 
(DIVA) study confirmed the non-inferiority 
of intermittent intravenous dosing regimens 
of ibandronate (either 2 mg every 2 months 
or 3 mg every 3 months) in terms of BMD 
improvement and tolerability over 2 years of 
treatment.139
    10.3.5 Intermittent intravenous ibandronate has 
also been shown to improve BMD and 
reduce the incidence of vertebral fracture in 
glucocorticoid-treated subjects.140
10.4 Preparations: Ibandronate is available as an 
oral 150-mg tablet given monthly or as a 3-mg 
intravenous injection administered every 3 
months.
10.5 Adverse effects: Up to 10% of subjects receiving 
the oral or intravenous regimens reported mild-to-
moderate influenza-like symptoms within 3 days 
of drug administration, usually during the initial 
administrations.137,139
10.6 Short-term 6-month cross-over studies 
demonstrated stronger patient preference for 
monthly ibandronate over weekly alendronate, 
which might imply a higher level of long-term 
adherence and compliance with therapy with 
ibandronate treatment.141,142
10.7 Recommendations: The lack of data on risk 
reduction for hip fracture and the fact that 
significant non-vertebral fracture risk reduction 
was only demonstrated in a post-hoc analysis of a 
high-risk subgroup would make ibandronate a less 
favourable bisphosphonate option for treatment 
of postmenopausal osteoporosis. However, 
with its more convenient intermittent monthly 
oral or 3-monthly intravenous dosing regimens, 
ibandronate may have an advantage for certain 
patient subgroups for whom adherence to therapy 
poses a significant consideration.
11. Zoledronic acid
11.1 Zoledronic acid is the most potent bisphosphonate 
currently available, and was approved by the 
FDA in 2007 for treatment of postmenopausal 
osteoporosis.
11.2 Efficacy
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    11.2.1 In the Health Outcomes and Reduced 
Incidence with Zoledronic Acid Once Yearly 
(HORIZON) Pivotal Fracture Trial (PFT), 
zoledronic acid at a dose of 5 mg given as 
an annual intravenous infusion significantly 
reduced the incidence of morphometric 
vertebral fracture by 70%, non-vertebral 
fracture by 25%, and hip fracture by 41% in 
postmenopausal osteoporotic women. There 
was a concomitant significant 6.7% BMD 
improvement at the spine and 6.0% at the total 
hip at 36 months.143
    11.2.2 Zoledronic acid is the first anti-osteoporosis 
medication which has demonstrated survival 
benefit in an RCT. In the HORIZON Recurrent 
Fracture Trial (RFT), zoledronic acid infusion 
administered within 90 days after hip fracture 
surgery was associated with a 28% reduction 
in all-cause mortality in a group of 1065 men 
and women followed up for a median of 1.9 
years.144 Exploratory analysis showed that 
zoledronic acid–treated subjects were less 
likely to die from pneumonia and arrhythmias 
than placebo-treated subjects.145 The exact 
underlying mechanism responsible for the 
improved survival is yet to be elucidated.
    11.2.3 A RCT involving 1199 men with primary or 
hypogonadism-associated osteoporosis 
also showed a significant 67% reduction in 
vertebral fracture after 24 months’ treatment.146
    11.2.4 A recent report also showed that zoledronic 
acid was non-inferior to, and possibly more 
effective than, oral risedronate for prevention 
and treatment of glucocorticoid-induced 
osteoporosis.147
11.3 Long-term data: In the 3-year HORIZON-PFT 
Extension Study, subjects who were randomised to 
receive a total of 6 years’ zoledronic acid therapy 
had a lower risk of new morphometric vertebral 
fracture than those who were randomised to 
placebo after an initial 3-year active treatment 
period in the core study (odds ratio [OR]=0.51; 
P=0.035), whereas other types of fractures were not 
different.148 There were no cases of atypical femur 
fracture and there was one case of osteonecrosis 
of the jaw (ONJ), which resolved with appropriate 
treatment.148
11.4 Preparation: Zoledronic acid is prescribed as a 
5-mg slow intravenous infusion over a minimum 
of 15 minutes once yearly. A longer infusion 
time is preferred for patients with pre-existing 
renal impairment. Zoledronic acid is contra-
indicated in patients with creatinine clearance of 
<35 mL/min/1.73 m2.
11.5 Adverse effects
    11.5.1 The most frequent side-effect is a post-dose 
flu-like syndrome with pyrexia, myalgia, and 
bone and musculoskeletal pain, which may 
last for a few days after the first infusion. 
Prophylactic paracetamol may be useful to 
decrease the severity of the syndrome. Post-
dose syndrome usually becomes less severe 
with repeated dosing.
    11.5.2 No adverse effects on fracture healing 
were noted in the HORIZON-RFT, in which 
zoledronic acid was administered within 90 
days post-hip fracture surgery.144
    11.5.3 An initial report of a significant increase in 
the risk of serious atrial fibrillation (1.3% 
in the treated group vs 0.5% in the placebo 
group)143 was not confirmed in subsequent 
studies.144,146,147
    11.5.4 Renal impairment and renal failure have 
been observed (18 cases per 100 000 patient-
years) following administration of intravenous 
zoledronic acid. Risk factors include pre-
existing renal impairment, advanced age, 
concomitant nephrotoxic medications, 
concomitant diuretic therapy or dehydration. 
Appropriate hydration must be ensured 
and monitoring of renal function should be 
considered for at-risk patients.149
11.6 Recommendations
    11.6.1 With its proven efficacy in reduction of 
vertebral, non-vertebral and hip fractures, 
zoledronic acid is recommended as one 
of the first-line drugs for treatment of 
postmenopausal osteoporosis. Zoledronic 
acid is especially indicated for patients with 
recent hip fractures, contra-indications 
for oral bisphosphonate therapy, existing 
polypharmacy or poor compliance with oral 
medications.
12. Teriparatide (recombinant-human parathyroid 
hormone 1-34)
12.1 Teriparatide was approved by the FDA in 2002 
as the only bone-forming agent for treatment of 
postmenopausal osteoporosis.
12.2 Teriparatide is structurally the 1-34 amino-terminal 
fragment of the human parathyroid hormone (PTH). 
It is the first pure bone-forming agent for treatment 
of osteoporosis. Intermittent PTH administration 
increases cortical and trabecular thickness and 
bone diameter, and improves bone strength and 
architecture.
12.3 Efficacy
    12.3.1 In the Fracture Prevention Trial (FPT), 
subcutaneous injection of teriparatide at 
a dose of 20 μg daily reduced the relative 
risk of vertebral fracture by 65% and that 
of non-vertebral fracture by 53% after a 
median treatment duration of 21 months in 
postmenopausal osteoporotic women. There 
was a concomitant significant 9% increase in 
BMD at the spine and 3% increase at the hip.150
    12.3.2 Histomorphometry and microcomputed 
tomography of 51 paired iliac crest biopsy 
specimens from women treated with 
teriparatide in the FPT revealed significant 
increases in cancellous bone volume, 
cancellous bone connectivity density, 
cancellous bone plate-like structure and 
cortical thickness, and a reduction in marrow 
star volume.151
    12.3.3 Improvement of BMD has also been reported 
in men with osteoporosis152 and in subjects 
with glucocorticoid-induced osteoporosis, 
in which the BMD gain was better with 
teriparatide than with alendronate.153
#		Guideline	for	Clinical	Management	of	Postmenopausal	Osteoporosis	# 
	 Hong	Kong	Med	J		Vol	19	No	2	#	Supplement	2	#		April	2013	 21
    12.3.4 There is no therapeutic synergy when 
combining teriparatide with antiresorptive 
drugs. In fact, bisphosphonates would 
attenuate PTH-induced stimulation of bone 
formation.154,155
    12.3.5 Treatment with teriparatide can achieve 
significant improvement in BMD regardless of 
previous long-term exposure to antiresorptive 
therapies, although prior antiresorptive 
treatment would modestly blunt the BMD 
response to teriparatide.156,157
    12.3.6 Bone loss occurs after stopping teriparatide, 
and it is recommended that teriparatide 
treatment should be followed by 
bisphosphonates or SERM to maintain the 
gain in BMD.158,159
    12.3.7 A meta-analysis of five clinical trials showed 
that teriparatide-treated subjects had 40-60% 
lower incidence of new or worsening back 
pain than placebo-, alendronate-, or HRT-
controlled subjects.160
12.4 Preparations: Teriparatide is prescribed as a daily 
20 μg subcutaneous injection and is approved for a 
treatment duration of up to 24 months.
12.5 Adverse effects: Adverse effects are mild and 
transient. They include nausea, headache, and 
orthostatic hypotension. Transient asymptomatic 
hypercalcaemia has been observed in about 5% of 
patients, but it is not clinically necessary to monitor 
calcium levels during therapy.
12.6 Contra-indications: Contra-indications include 
a history of skeletal malignancy or irradiation 
involving the skeleton, Paget’s disease, unexplained 
elevated bs-ALP and any form of untreated or 
unresolved hyperparathyroidism.
12.7 Recommendations: Due to its bone-forming 
action, significant improvement of bone 
microarchitecture, and proven efficacy in 
reduction of vertebral and non-vertebral fractures, 
teriparatide is recommended as one of the first-
line drugs for treatment of postmenopausal 
osteoporosis. Teriparatide is especially indicated 
in patients with established osteoporosis (≥1 
osteoporotic fractures), with very low BMD (T-
score < –3), who experience fracture while taking 
antiresorptive therapies, or with continuing bone 
loss despite appropriate antiresorptive therapies 
after exclusion of non-compliance and secondary 
causes. The main limitations to the widespread use 
of teriparatide are its relatively high cost and the 
need for daily subcutaneous injection.
13. Strontium ranelate
13.1 Strontium ranelate is an anti-osteoporosis drug 
with a novel mechanism of action that is different 
from that of the conventional antiresorptive or 
bone-forming agents. Although the mechanism 
of its molecular mode of action has not been fully 
elucidated, strontium ranelate appears to dissociate 
bone remodelling to increase bone formation and 
decrease bone resorption.
13.2 In-vitro strontium ranelate stimulates proliferation 
of pre-osteoblasts and their differentiation 
into mature osteoblasts, while inhibiting 
osteoclastogenesis and the bone resorption activity 
of mature osteoclasts.161
13.3 Efficacy
    13.3.1 The Spinal Osteoporosis Therapeutic 
Intervention (SOTI) and Treatment of 
Peripheral Osteoporosis (TROPOS) 
studies confirmed that treatment with oral 
strontium ranelate at a dose of 2 g daily in 
postmenopausal women for 3 years reduced 
the risk of new vertebral and non-vertebral 
fractures by 41% and 16%, respectively, with a 
concomitant uncorrected increase of BMD of 
14% at the spine and 8-10% at the hip.162,163
    13.3.2 A post-hoc analysis showed a significant 
36% reduction in hip fracture in a high-risk 
subgroup of women aged 74 years or older 
and with femoral neck BMD of ≤ –3.163
    13.3.3 The anti-fracture efficacies at the spine 
and non-vertebral sites, including the hip, 
were maintained in an extension study, with 
randomisation maintained for up to 5 years.164
    13.3.4 In a pre-planned pooled subgroup analysis of 
1488 very elderly women, aged 80-100 years, 
treated with strontium ranelate for 3 years, the 
risks of vertebral, non-vertebral, and clinical 
fractures were significantly reduced by 32%, 
31%, and 22%, respectively. A significant anti-
fracture effect was already evident within 1 
year, with a risk reduction for vertebral, non-
vertebral, and clinical (symptomatic) fractures 
of 59%, 41%, and 37%, respectively.165
    13.3.5 In another subgroup analysis involving 353 
young postmenopausal women, aged 50-65 
years, with vertebral fracture at baseline, 
strontium ranelate treatment for 4 years 
significantly reduced the risk of vertebral 
fracture by 35%.166
    13.3.6 In women with lumbar spine osteopenia, 
strontium ranelate treatment for 3 years 
significantly reduced the risk of vertebral 
fracture by 41% and, in women with 
osteopenia at both the lumbar spine and 
femoral neck, treatment significantly reduced 
the risk of vertebral fracture by 52%.167
    13.3.7 A study of Asian women has shown a significant 
3-5% increase in BMD over 1 year in the lumbar 
spine, femoral neck, and total hip BMD in the 
strontium ranelate–treated group compared 
with the placebo group, and its effect on BMD 
and safety profile were consistent with those 
reported from Caucasian studies.168
    13.3.8 Data on male osteoporosis are emerging. Two 
short-term studies showed that strontium 
ranelate produced significantly greater 
increases in lumbar spine and femoral neck 
BMD in male osteoporotic subjects at 12 
months, with a magnitude comparable to 
those previously observed in postmenopausal 
women.169,170
    13.3.9 At present, there are no data on the combined 
use of strontium ranelate with other anti-
osteoporosis agents, and neither are there any 
data on glucocorticoid-induced osteoporosis.
13.4 Long-term data: Five-year extension follow-up data 
showed a continuous improvement in lumbar 
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BMD over a 10-year period and a continuous 
improvement in total hip and femoral neck BMD 
for up to 7 years; the cumulative incidences of new 
vertebral and non-vertebral fractures in the 5-year 
extension study was statistically similar to those in 
the first 5 years, despite a theoretical increase in 
fracture risk with ageing.171
13.5 Extra-skeletal benefits: A post-hoc analysis of 
pooled data from the SOTI and TROPOS trials 
involving 1105 women with concomitant baseline 
radiological spinal osteoarthritis showed that the 
proportion of patients with worsening overall spinal 
osteoarthritis score in the lumbar radiographs 
was significantly reduced by 42% in the strontium 
ranelate group and significantly more patients in 
the treatment group experienced improvement in 
back pain after 3 years compared with the placebo 
group, suggesting that strontium ranelate could 
reduce progression of the radiographic features of 
spinal osteoarthritis and back pain in women with 
osteoporosis and prevalent spinal osteoarthritis.172
13.6 Preparation: Strontium ranelate is prescribed as a 
powder suspension to be taken orally at night at a 
dose of 2 g daily. Food should be avoided for at least 
2 hours before and after its ingestion and it must 
not be taken with calcium tablets.
13.7 Adverse effects 
    13.7.1 Common adverse effects include headache, 
nausea, diarrhoea, and skin rash.
    13.7.2 In a recent safety review by the EMA in March 
2012, it was noted that strontium ranelate was 
associated with an increase in risk of VTE in 
patients with a history of VTE, those who are 
temporarily or permanently immobilised and 
in elderly patients older than 80 years, so 
the EMA has recommended that strontium 
ranelate should no longer be given to 
immobilised patients or patients with VTE, and 
its use in elderly patients older than 80 years 
should be re-evaluated.173
    13.7.3 The EMA also issued an update to warnings 
regarding potentially fatal serious skin 
reactions such as drug rash eosinophilia 
and systemic symptoms (DRESS) syndrome, 
Stevens-Johnson syndrome, and toxic 
epidermal necrolysis (TEN) to alert health 
care professionals and patients to the likely 
signs and symptoms of these conditions for 
immediate drug discontinuation.173
13.8 Contra-indications: Strontium ranelate is contra-
indicated in patients with a history of or current 
VTE or in immobilised patients.173 
13.9 Recommendations: With its proven efficacy in 
reduction in risk of vertebral and non-vertebral 
fractures in RCTs and reduction in hip fracture in 
post-hoc analysis of a high-risk group, strontium 
ranelate can be considered as an oral alternative 
for patients with a history of upper gastrointestinal 
disorders that may be a contra-indication for oral 
bisphosphonate therapy, but the benefit-risk 
ratio in elderly patients older than 80 years needs 
to be carefully evaluated. A special alert to the 
development of severe skin reactions needs to be 
emphasised. 
14. Denosumab
14.1 Denosumab was approved by the FDA in June 2010 
as an injectable treatment for postmenopausal 
osteoporosis.
14.2 Denosumab is a fully human monoclonal antibody 
that specifically binds to the receptor activator of 
nuclear factor-kappa B ligand (RANKL), a cytokine 
that is essential for the differentiation, activity, 
and survival of osteoclasts. By binding to RANKL, 
denosumab prevents the interaction of RANKL with 
its receptor, RANK, on osteoclasts and osteoclast 
precursors and reversibly inhibits osteoclast-
mediated bone resorption.174
14.3 Following a single subcutaneous dose, serum 
denosumab levels decline over a period of 4-5 
months, with a mean half-life of approximately 26 
days. Clearance of denosumab occurs through the 
reticuloendothelial system, and is thus independent 
of renal clearance so that no dosage adjustment is 
necessary for patients with renal impairment.175
14.4 Efficacy
    14.4.1 In the Fracture Reduction Evaluation of 
Denosumab in Osteoporosis Every 6 Months 
(FREEDOM) trial, denosumab at a dose of 60 
mg given as a subcutaneous injection every 6 
months for 36 months significantly reduced 
the risk of new radiographic vertebral 
fracture by 68%, risk of hip fracture by 40%, 
and risk of non-vertebral fracture by 20% in 
postmenopausal women, with a concomitant 
increase in BMD of 9.2% at the spine and 6% 
at the total hip.176 The reduction in risk of new 
radiographic vertebral fracture was similar 
during each year of the study at 61%, 78% 
and 65% in the first, second and third years of 
treatment respectively.176
    14.4.2 In a post-hoc analysis of the FREEDOM 
study, the treatment efficacy and incidence 
of adverse events were shown to be similar 
between patient subgroups stratified by the 
level of renal function from stage 1 (estimated 
glomerular filtration rate [eGFR] ≥90 mL/min) 
to stage 4 (eGFR 15-29 mL/min) chronic kidney 
disease.177
    14.4.3 An off-treatment study demonstrated that the 
treatment effects of denosumab on both BMD 
and BTMs were reversible. BMD declined back 
to baseline at all sites after 24 months and 
BTMs rapidly increased above baseline within 
3-6 months of discontinuation and returned 
to baseline by 48 months. This observation 
of reversibility is consistent with the current 
knowledge that denosumab does not persist 
in bone tissues.178
    14.4.4 When compared with oral alendronate in 
a 12-month comparison trial, denosumab 
showed significantly larger gains in BMD at 
all measured skeletal sites and achieved a 
significantly greater reduction of BTMs.179
    14.4.5 Transition to denosumab for patients 
previously taking alendronate produced 
greater increases in BMD at all measured 
skeletal sites and a greater reduction in bone 
turnover than did continued alendronate over 
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a 12-month period.180
    14.4.6 The Preference and Satisfaction Questionnaire 
(PSQ) study showed that patients had a greater 
preference for, and were more satisfied with, a 
6-month injection regimen than a weekly oral 
regimen for osteoporosis treatment.181
    14.4.7 In the Denosumab Adherence Preference 
Satisfaction (DAPS) study, a 24-month, 
randomised, open-label, crossover 
comparison with alendronate in 250 
postmenopausal osteoporotic women, 
subjects were more adherent, compliant, and 
persistent with subcutaneous denosumab 
injections every 6 months than with once-
weekly alendronate tablets, and they reported 
increased treatment preference (92.4%) and 
satisfaction with injectable denosumab over 
oral alendronate.182
    14.4.8 Male treatment data with fracture as an 
endpoint are also available. In a RCT involving 
1468 men who had received androgen-
deprivation therapy for non-metastatic 
prostate cancer, denosumab was associated 
with increased BMD at all sites, and a 
significant 62% reduction in the incidence of 
new vertebral fracture at 24 months.183
    14.4.9 Another RCT of 242 men with low bone 
mass also showed significant improvement 
in BMD at all skeletal sites and a significant 
reduction in bone markers levels after 1 year 
of denosumab treatment.184
14.5 Adverse effects: In the initial 3-year FREEDOM 
trial, there was a higher incidence of eczema and 
serious cellulitis in the denosumab-treated group; 
otherwise, there were no significant differences in 
the risk of cancer, infection, cardiovascular disease, 
delayed fracture healing or hypocalcaemia, and 
there were no cases of ONJ or atypical femur 
fracture.176
14.6 Long-term data
    14.6.1 The 2-year FREEDOM Extension Study showed 
that reduction in BTMs were maintained and 
BMD increased further, resulting in total 
5-year BMD gains of 13.7% and 7.0% in the 
lumbar spine and total hip, respectively, and 
the annual fracture incidence was below 
the rate observed in the FREEDOM placebo 
group.185 
    14.6.2 The incidence of eczema and cellulitis was not 
increased in the Extension Study.185
    14.6.3 ONJ developed in two patients who crossed 
over from the placebo group to receive 
denosumab in the extension phase, and 
had healed completely within 137 and 227 
days. There were no cases of atypical femur 
fracture.185
    14.6.4 Reports of ONJ have also recently been 
reported in patients treated with denosumab 
for cancer and skeletal metastases.186-188
    14.6.5 Given its relative short post-marketing period, 
vigilance regarding potential serious adverse 
effects such as ONJ and atypical femur 
fracture is advised.
14.7 Preparation: Denosumab is given at a dose of 60 mg 
by subcutaneous injection every 6 months.
14.8 Recommendations: With its proven efficacy 
in reduction of vertebral, non-vertebral and 
hip fractures, denosumab is recommended 
as one of the first-line drugs for treatment of 
postmenopausal osteoporosis. Denosumab is 
especially indicated in patients with polypharmacy, 
poor compliance to oral drugs, contra-indications 
to oral bisphosphonate therapy, who cannot 
tolerate oral or intravenous bisphosphonate 
therapies, or who have suboptimal BMD responses 
to other antiresorptive therapies. Denosumab 
may also serve as an option for switching from 
bisphosphonates for high-risk patients who have 
been taking prolonged bisphosphonate treatment. 
There is no contra-indication for its use in patients 
with renal impairment up to stage 4 chronic kidney 
disease.
(I) Indications for Osteoporosis Treatment
1. Patients at high risk for fracture should be treated 
with specific anti-osteoporosis drugs. In general, 
the treatment guidelines recommended by the US 
NOF are widely adopted,39 as follows:
 (i) prior low-energy hip or vertebral fractures
 (ii) BMD T-score of ≤ –2.5 at the lumbar spine or 
proximal femur on DXA scan
 (iii) low bone mass (T-score between -1 and -2.5) 
and one of following:
  (a) 10-year probability of any major 
osteoporotic fracture of ≥20% computed 
by the US-adapted WHO FRAX algorithm
  (b) 10-year probability of hip fracture of ≥3% 
computed by the US-adapted WHO FRAX 
algorithm
2. These US criteria are for clinical guidance only. All 
treatment decisions require clinical judgement 
and consideration of individual patient factors, 
including patient preferences, co-morbidities, 
quality of life, life expectancy, and other risk factors 
not captured in the FRAX model such as frailty and 
falls. The decision to treat must be made on a case-
by-case basis.
(J) Monitoring of Osteoporosis Treatment
1. General considerations
1.1 Osteoporosis is a chronic disease and patients 
receiving treatment should be monitored for:
 (i) efficacy of treatment
 (ii) adequacy of calcium and vitamin D intake 
(from diet or supplementation)
 (iii) side-effects of medications
 (iv) adherence to therapy
 (v) new co-morbidities or medications that might 
alter the expected treatment effect
1.2 Monitoring for treatment efficacy is limited by the 
absence of clinical tools that directly measure bone 
strength so that it is necessary to monitor therapy 
with surrogate markers such as BMD and BTMs.
2. Role of bone mineral density in monitoring
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2.1 Measurement of BMD by DXA as a surrogate 
marker of treatment efficacy has been widely used 
in clinical trials, but the value of serial densitometry 
for monitoring osteoporosis treatment is still a 
subject of controversy.189
2.2 Accurate detection of BMD changes during 
treatment requires that the change is greater than 
the precision error of the measurements. From 
a strictly statistical viewpoint, to detect the least 
significant change (LSC) at the 95% confidence 
level, the BMD changes have to be at least 2.8 
times the precision error.190 The precision error, 
in turn, depends on equipment error, technician 
variability, differences in patient positioning, and 
other technical artefacts. To minimise precision 
error, serial BMD measurements should ideally 
be performed with the same instrument and 
preferably by the same technologist.
2.3 Quantitative comparison of BMD measured 
with different instruments made by the same 
manufacturer or by different manufacturers cannot 
be made because of errors associated with possible 
differences in software, method of dual-energy 
production, calibration, bone edge detection and 
regions of interest unless cross-calibration has 
been done.191
2.4 Long-term precisions of 1.12%, 1.32%, and 2.21% 
have been obtained for the lumbar spine, total hip, 
and femoral neck BMD, respectively.192 Therefore, 
a repeat densitometry study cannot be interpreted 
unless the variation is at least 3% at the spine and 
4-6% at the femoral neck or total hip respectively. 
Since the mean gain in BMD at the spine after 1 
year of most antiresorptive treatments is likely 
to be within the precision error, an interval of at 
least 2 years is needed in most cases to identify 
responding patients.
2.5 Change in BMD, however, is not a sensitive 
surrogate marker to predict fracture risk reduction 
with antiresorptive treatment. Current evidence 
shows that increases in BMD can only explain 
7-18% of the fracture risk reduction associated 
with bisphosphonate treatment193-195 and 4% of the 
vertebral fracture risk reduction associated with 
raloxifene treatment.103 This evidence suggests that 
factors other than BMD are important for fracture 
risk reduction.
2.6 On the other hand, the gain in BMD during 
treatment with a bone-forming agent accounts for a 
more significant proportion of the observed clinical 
fracture risk reduction. Teriparatide-mediated 
increases in spine BMD accounted for 30-41% of 
the reduction in vertebral fracture risk.196
2.7 The highest prediction was seen in strontium 
ranelate–treated patients, in whom the 3-year 
changes in femoral neck and total proximal femur 
BMD explained 76% and 74%, respectively, of the 
reduction in vertebral fractures at 3 years. Each 
percentage point increase in femoral neck and 
total proximal femur BMD was calculated to be 
associated with a 3% and 2% reduction in risk of a 
new vertebral fracture, respectively.197
2.8 Despite controversy about the use of BMD for 
monitoring, both the NOF and the International 
Society for Clinical Densitometry (ISCD) 
recommend BMD measurements for routine 
monitoring of treatment.39,198 The NOF advocates 
that repeat measurements should normally be 
made every 2 years,39 whereas the ISCD advocates 
that the first follow-up measurement should be 
performed 1 year after initiation or change of 
therapy with “longer intervals once the therapeutic 
effect is established.”198
2.9 Recommendations for BMD monitoring:
 (i) a repeat BMD measurement should be 
performed 1-2 years after initiation of 
antiresorptive treatment and preferably 1 year 
after treatment with agents with bone-forming 
properties
 (ii) BMD monitoring can then be performed at 2- 
to 3-year intervals after the therapeutic effect 
is established
 (iii) taking into account the concept of LSC, a 
BMD loss of 0-4% for most DXA facilities in 
an individual patient should be interpreted as 
stable or no significant loss of BMD
 (iv) patients who have a significant decrease 
in BMD (≥4%) despite treatment should 
be evaluated for adherence to treatment, 
inadequate calcium and/or vitamin D intake, 
poor drug absorption, or presence of 
previously unrecognised secondary causes of 
osteoporosis
2.10 Feedback of BMD results to patients may improve 
treatment adherence; however, the exact impact 
of BMD monitoring on adherence needs to be 
assessed.
3. Role of bone turnover markers in monitoring
3.1 Changes in BTMs are much more rapid than the 
changes in BMD.
3.2 With most effective antiresorptive therapies, BTMs 
decrease rapidly and reach a drug- and dose-
dependent plateau within a few months.199 Short-
term reduction in BTMs have also been shown to 
correlate with the longer-term BMD response to 
therapy199 and reduction in fracture risk.199-202
3.3 For the bone-forming agent teriparatide, an early 
increase in levels of bone formation markers is 
predictive of a subsequent increase in BMD,203 
whereas the predictive value of changes in levels of 
bone formation markers for strontium ranelate has 
not been reported.
3.4 Although there is an absence of authoritative 
clinical practice guidelines for the use of BTMs, 
there is emerging support for their use in 
monitoring treatment response, especially within 
the first 3-6 months of initiation of antiresorptive 
therapy when BMD changes are too small to be 
detected clinically.
3.5 The clinical value of BTMs for monitoring is 
currently limited by inadequate appreciation of the 
sources of measurement variability, by limited data 
for comparison of treatments using the same BTM 
and by inadequate quality control.
3.6 The IOF and the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC), in their 
recent joint position paper, recommended one 
bone formation marker (serum P1NP) and one 
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bone resorption marker (serum C-telopeptide) to 
be used as reference markers, and measured by 
standardised assays in clinical studies in order to 
compare the performance of alternative markers 
and to enlarge the international experience of the 
application of markers to clinical medicine.204
4. Monitoring adherence to therapy
4.1 Treatment of osteoporosis will not be effective 
unless the patient is taking the prescribed anti-
osteoporosis medication regularly and correctly, 
together with adoption of a healthy lifestyle.
4.2 A systematic review showed that patients taking 
weekly bisphosphonate preparations had better 
compliance and a higher persistence rate than 
those taking daily preparations, but the overall 
1-year persistence rate with bisphosphonate 
therapy was still suboptimal at around 17.9-78.0%.205
4.3 The reasons for low persistence may include lack 
of immediate patient-recognised benefits, real or 
perceived adverse effects, costs, and inconvenient 
dosing.
4.4 Less frequent dosing appears to be associated 
with improved persistence and compliance. 
Analyses of data from different prescription 
databases consistently reported that once-monthly 
ibandronate was associated with significantly 
improved treatment persistence and compliance 
relative to weekly bisphosphonates at 1 year.206-209 
4.5 Intravenous bisphosphonates given at longer 
dosing intervals have also been reported to have 
a higher preference rate (>75%) by patients over 
oral bisphosphonates in short-term studies of 12 
months’ duration.210,211
4.6 Preference for 6-monthly denosumab injection 
over weekly oral alendronate has also been 
demonstrated in two studies.181,182
4.7 Patients with better compliance and higher 
persistence have a better clinical outcome. Poor 
compliance was associated with suboptimal 
increases in spinal BMD.212 All reported studies 
consistently demonstrated that good compliance 
and high persistence significantly reduced fracture 
rates.212,213 A recent meta-analysis of six studies 
involving 171 063 patients followed up for 1.0-2.5 
years provided a pooled 46% increase in fracture 
risk in non-bisphosphonate–compliant patients 
versus bisphosphonate-compliant patients.213
4.8 In a randomised study comparing the adherence 
rate of raloxifene at 1 year among three groups of 
patients receiving nurse interview monitoring every 
12 weeks, BTM monitoring every 12 weeks and no 
monitoring, the monitored groups were found 
to have an increase in cumulative adherence to 
therapy by 57% compared with the no-monitoring 
group, and there was no difference in cumulative 
adherence between the nurse-monitored and BTM-
monitored groups.214 BTM monitoring, in addition 
to regular contact by nurses, may further improve 
persistence with therapy.
4.9 It is recommended that follow-up contact with a 
health care professional within several months 
of starting treatment should be considered. This 
serves as an opportunity to determine whether the 
patient:
 (i) takes the medication regularly and correctly
 (ii) develops any side-effects or concerns about 
possible side-effects
 (iii) has an adequate intake of calcium and vitamin 
D
 (iv) has adopted a healthy lifestyle such as 
avoidance of smoking and excess alcohol, 
regular physical activities and exposure to 
sunlight
(K) Bisphosphonate-Related Osteonecrosis 
of the Jaw 
1. Bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) is defined as an area of uncovered bone in 
the maxillofacial region that does not heal within 8 
weeks after identification by a health care provider 
in a patient who is receiving or has been exposed 
to bisphosphonate therapy, without previous 
radiation therapy to the craniofacial region after 
exclusion of malignancy.215
2. BRONJ is not an uncommon problem when 
bisphosphonates are given at high accumulated 
doses for treatment of malignant bone diseases 
or Paget’s disease.216 The risk of BRONJ in cancer 
patients treated with high doses of intravenous 
bisphosphonates is estimated to be in the range of 
1-10 per 100 patients.217
3. Reports of BRONJ in patients treated with oral 
bisphosphonates at a low dose for osteoporosis 
are notably few. Four cases have been reported 
from Hong Kong.218,219 Cases are commonly related 
to tooth extraction, occasionally to other dental 
trauma and even occur spontaneously.
4. The reported population incidences of BRONJ are 
very low, ranging from 0.00038% in Germany220 to 
0.07% in Korea,221 and the risk of BRONJ associated 
with oral bisphosphonate therapy for osteoporosis 
has been estimated to be between 1 in 10 000 and 
<1 in 100 000 treatment years.217
5. In the largest Asian series reported from Korea, of 
the 95 cases of ONJ identified over a 3-year period 
in a university maxillofacial centre, less than one-
third (24 cases) were found to be related to oral 
bisphosphonate treatment for osteoporosis.221
6. The two most important risk factors for ONJ are the 
presence of malignancy and prior chemotherapy. 
Studies in cancer patients suggest other risk 
factors are involved, including high potency of 
the bisphosphonate, long treatment duration, 
preceding dentoalveolar surgery, concomitant oral 
diseases such as periodontal abscess, older age, 
smoking, alcohol abuse, and presence of co-morbid 
medical diseases, notably diabetes, corticosteroid 
therapy, renal dialysis, and anaemia.215,217
7. Since the background incidence rate of ONJ in the 
general population unexposed to bisphosphonates 
is not known, the current level of evidence does 
not support a direct cause-and-effect relationship 
between oral bisphosphonates and ONJ. The 
current data do not suggest a significant impact on 
the risk-benefit ratio for the use of bisphosphonates 
in osteoporosis treatment. However, physicians 
who prescribe bisphosphonates must be aware 
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of this very rare potential side-effect, and patients 
receiving bisphosphonate treatment should be 
informed of the need to maintain adequate levels 
of dental hygiene with routine dental care.
8. According to recommendations from the Task 
Force of the American Society for Bone and Mineral 
Research (ASBMR), patients with periodontal 
disease taking oral bisphosphonate treatment 
should receive appropriate non-surgical therapy. 
Endodontic treatment is preferable to extraction or 
periapical surgery when possible. There are no data 
to suggest that stopping the bisphosphonate will 
improve dental outcomes given the long retention 
of bisphosphonates in the skeleton.217
9. For intravenous zoledronic acid, in the HORIZON-
PFT Core and Extension studies, two cases of ONJ 
were reported in the active treatment group, one 
during the core study and the other during the 
extension phase, while one case was reported in the 
placebo group during the core study.148 At present, 
there have been no findings to suggest a difference 
in the risk of ONJ associated with the intravenous 
route of administration at the doses approved for 
osteoporosis compared with oral bisphosphonate 
therapy for management of osteoporosis.
(L)  Atypical Femur Fractures
1. General considerations
1.1 Fractures located in the subtrochanteric/diaphyseal 
regions account for 7-10% of all fractures of 
the femur.222 Epidemiological studies show that 
fractures at these regions follow an age and sex 
distribution similar to typical osteoporotic hip 
fractures.
1.2 There are recently published case reports and 
case series on the occurrence of atypical femur 
(subtrochanteric/diaphyseal) fractures in patients 
taking oral bisphosphonates for osteoporosis, 
including two reports from Hong Kong.223-227
1.3 Atypical femur fracture refers to a special type 
of fracture occurring in the subtrochanteric/
diaphyseal region with characteristics of ‘atypia’. To 
standardise comparison, a unified case definition 
of atypical femur fracture with major and minor 
atypia features was developed by a special Task 
Force appointed by the ASMBR in 2010 (Table 8228). 
All major features need to be present in order to 
designate a fracture as ‘atypical’. Minor features 
that have been described in some reports may or 
may not be present in individual patients.228
1.4 Atypical femur fractures can occur in patients who 
have not been treated with bisphosphonates, and 
their true incidences in treated and untreated 
patients are unknown.
1.5 Radiologically, atypical femur fractures bear striking 
similarities to stress/insufficiency fractures, but the 
exact pathogenetic mechanisms have not been 
fully defined. Postulated mechanisms include:
 (i) excessive suppression of bone remodelling by 
bisphosphonates resulting in accumulation of 
microdamage223,225
 (ii) alterations to the normal pattern of collagen 
maturity and cross-linking in the organic 
bone matrix, and bone mineralisation density 
distribution by bisphosphonates228
 (iii) reduction in bone vascularity and angiogenesis 
by bisphosphonates229 
1.6 Bone biopsies from patients with atypical femur 
fractures do not universally support the theory of 
excessive suppression of bone turnover.230
1.7 The association between bisphosphonate use and 
atypical femur fracture is discussed in detail in the 
following sections.
2. Evidence from epidemiology of femur fractures
2.1 Despite the widespread clinical use of 
bisphosphonates since 1995, the number of 
admissions for subtrochanteric/diaphyseal femur 
fractures in the US remained unchanged from 1996 
to 2006 both in men and women with an annual 
incidence in women of <30 per 100 000 person 
years.222 The number of admissions for femoral 
shaft fracture was also unchanged from 1998 to 2004 
in Sweden.231
2.2 However, the annual incidence of conventional 
hip fractures (femoral neck, and trochanteric and 
intertrochanteric regions) in women decreased 
from about 600 per 100 000 to 400 per 100 000 
person-years during the decade after 1996.222
2.3 These findings confirmed that conventional hip 
fracture incidence has significantly declined since 
bisphosphonates were approved for clinical use 
without a concomitant increase in subtrochanteric/
diaphyseal femur fractures. However, a stable 
incidence with no decrease in the number of 
subtrochanteric/diaphyseal fractures does not 
exclude the possibility of a shift from typical 
osteoporotic to atypical fractures at these sites.
Table 8. Atypical femur fracture: major and minor features228
Major features Location anywhere along the femur from the lesser trochanter to the proximal supracondylar flare
Associated with no or minimal trauma
Transverse or short oblique configuration
Non-comminuted
Complete fractures extend through both cortices and may be associated with a medial spike; incomplete 
fractures involve only the lateral cortex
Minor features Localised periosteal reaction of the lateral cortex
Generalised increase in cortical thickness of the diaphysis
Prodromal symptoms such as dull or aching pain in the groin or thigh
Bilateral fractures and symptoms
Delayed healing
Co-morbid conditions: vitamin D deficiency, rheumatoid arthritis, hypophosphatasia
Use of pharmaceutical agents: bisphosphonates, glucocorticoids, proton pump inhibitors
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3. Evidence from randomised clinical trials
3.1 In a recent secondary analysis involving 14 195 
women from three large randomised clinical 
trials (Fracture Intervention Trial [FIT], FIT Long-
term Extension [FLEX], and HORIZON-PFT), 12 
subtrochanteric/diaphyseal femur fractures were 
identified in 10 patients, three of whom were in the 
placebo groups.232
3.2 The occurrence of subtrochanteric/diaphyseal 
femur fractures was found to be rare, at a rate of 
2.3 per 10 000 patient years, even among women 
treated with alendronate for as long as 10 years, and 
there was no significant increase in risk associated 
with bisphosphonate use when compared with 
placebo, albeit with wide confidence intervals.232
3.3 The limitations of this analysis232 were that 
only a minority of patients received >4 years of 
alendronate treatment, some received a lower 
dose of alendronate (5 mg), radiographs were 
not available for evaluation of definite atypia and 
statistical power was extremely low because of the 
rarity of these fractures.
4. Evidence from cohort studies
4.1 Most of the information regarding the association 
between bisphosphonate use and atypical femur 
fractures are derived from cohort studies.
4.2 The reported duration of bisphosphonate use in 
patients with atypical femur fractures ranged from 
6 months to 17 years,227,228,233 with a median duration 
of 7.5 years.233 Several case-control cohort studies 
showed that the risk of atypical femur fractures 
correlated with the duration of bisphosphonate 
use.234-236
4.3 In the largest case-control cohort study published 
to date, 716 Canadian women with subtrochanteric/
diaphyseal femur fractures (ASBMR atypia criteria 
were not ascertained) were compared with 
9723 women with typical site osteoporotic hip 
fractures while taking bisphosphonate therapy. 
Bisphosphonate treatment for ≥5 years was 
significantly associated with an increased risk 
of subtrochanteric/diaphyseal femur fracture 
(adjusted OR=2.74).235
4.4 In the same Canadian cohort, extended 
bisphosphonate treatment for ≥5 years was also 
associated with a significantly reduced risk of typical 
site osteoporotic fractures (adjusted OR=0.76).235
4.5 In a Swedish National Registry in 2008 involving 
1 521 131 women aged 55 years or older, 12 777 
had fractures of the femur. Fifty-nine (0.4%) femur 
fractures were identified as atypical after review of 
the radiographs. Although the age-adjusted relative 
risk of atypical fracture with bisphosphonate 
use was high (relative risk=47.3), the increase in 
absolute risk was small (5 cases per 10 000 patient-
years), corresponding to an average number 
needed to harm of 2000 per year of use.236
5. Benefit-risk assessment of bisphosphonate use
5.1 Bisphosphonates are highly effective at reducing 
the risk of osteoporotic vertebral and non-vertebral 
fractures in at risk subjects.
5.2 The ASBMR, IOF, and FDA all stated that according 
to the current available evidence, there was no 
clear direct cause-and-effect relationship between 
the use of oral bisphosphonates and the risk of 
atypical femur fractures.228,233,237
5.3 The IOF and the European Society for Clinical 
and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO) jointly published a Position 
Paper in 2011 on atypical femur fracture.233 To assess 
the benefit-risk ratio of bisphosphonate use, the IOF 
and ESCEO have made the following evaluations. 
Assuming the average population risk of hip fracture 
to be 1% per year in postmenopausal women, 300 
hip fractures are expected for every 10 000 high-risk 
patients per year. If these patients were treated, 
and assuming an effectiveness of bisphosphonate 
therapy of 36% relative risk reduction, 108 hip 
fractures could be averted by treatment (and 
approximately 750 fractures at other sites). On the 
debit side, three subtrochanteric fractures (both 
typical and atypical) can be expected, which might 
increase to six if bisphosphonate therapy doubled 
the risk for all subtrochanteric fractures. The IOF 
and ESCEO concluded that the overall benefit-risk 
ratio remained favourable for bisphosphonate 
use.233
6. Clinical approach to atypical femur fractures
6.1 Clinicians must be vigilant to patients taking 
bisphosphonates especially when patients have 
symptoms of aching pain over the thigh and groin.
6.2 Conventional plain radiographs of the femur in 
anteroposterior and lateral projections may show 
characteristic findings of complete or incomplete 
fracture, including transverse/oblique fracture 
lines, focal (beaking) or diffuse cortical thickening, 
especially of the lateral cortex, and medial spike in 
complete fracture.
6.3 Subtle or non-diagnostic findings may require 
more sophisticated imaging such as technetium 
bone scan, magnetic resonance imaging (MRI) or 
computed tomography to detect early stages of 
stress or insufficiency fractures.
6.4 For complete fracture, since bisphosphonates 
inhibit osteoclastic remodelling, endochondral 
fracture repair with an intramedullary 
reconstruction nail is the preferred method of 
treatment.228 
6.5 For incomplete fracture, prophylactic 
reconstruction nail fixation is recommended if 
the fracture is accompanied by pain. If there is 
minimal pain, a trial of conservative therapy with 
limited weight bearing may be considered for 
2-3 months. Prophylactic nail fixation still needs 
to be considered if there are no symptomatic 
and radiographic improvements. If there is no 
associated pain, weight bearing may be continued, 
but vigorous activity must be avoided. Reduced 
activity should be continued until there is no bone 
oedema on MRI.228
6.6 Bilaterality has been shown to be present in around 
30% of subjects so the contralateral femur must 
always be evaluated radiographically.228
6.7 For medical treatment, potent antiresorptive agents 
should be discontinued. Adequate calcium and 
vitamin D status should be ensured. Teriparatide or 
strontium ranelate therapy may improve or hasten 
healing of these fractures according to anecdotal 
reports.238,239 
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(M) Duration of Bisphosphonate Treatment
1.  Oral bisphosphonates
1.1 There is currently no consensus for the optimal 
duration of treatment with bisphosphonates.
1.2 In the randomised FLEX study, during the 5 years 
following discontinuation of alendronate, women 
showed a moderate decline in BMD and a gradual 
rise in biochemical markers, but there were no 
significant differences in the cumulative risks of 
both morphometric vertebral and non-vertebral 
fractures compared with those who continued 
alendronate for a total of 10 years.240 However, 
there was a significant 55% reduction in risk of 
clinical vertebral fracture in women who continued 
alendronate.240
1.3 A post-hoc analysis of the FLEX study showed 
that, in women without vertebral fracture at 
baseline, continuation of alendronate for 10 years 
significantly reduced non-vertebral fracture by 50% 
in those whose femoral neck T-score remained 
≤ –2.5 after 5 years of alendronate therapy.241
1.4 Using data from the FLEX study to estimate the 
NNT for 5 additional years to prevent one clinical 
vertebral fracture in subgroups defined by BMD at 
the femoral neck and by prevalent vertebral fracture 
status (after 5 years of initial alendronate treatment) 
showed that the risk of vertebral fracture was 
highest and the NNTs were lowest for patients with 
a femoral neck T score of ≤ –2.5 (NNT=17 and 24 
for those with prevalent and no prevalent vertebral 
fracture respectively). On the other hand, the NNT 
is much higher (NNT=102) for those with no pre-
existing fracture and who achieved a femoral neck 
T-score of > –2.0 after an initial treatment period 
of 5 years.242 These data suggested that the former 
group of patients may reasonably be expected to 
benefit by continuing bisphosphonate therapy, 
whereas the latter group can discontinue treatment 
with a relatively low risk of subsequent vertebral 
fracture.
1.5 Recommendations: It is reasonable to reassess 
the need for continuing treatment after an initial 
treatment duration of 5 years. Decisions to continue 
treatment must be based on individual assessment 
of risks and benefits and on patient preference. 
Physicians should re-evaluate in the context of the 
indications for treatment, progress while receiving 
therapy, current BMD measurements, and current 
bone marker levels (if available), and risk factors 
for fracture. For those patients with high fracture 
risk and for those with an achieved femoral neck 
T-score of ≤ –2.5 after 5 years of treatment, it seems 
reasonable to continue treatment since the benefit-
risk ratio is well on the side of continued treatment. 
Patients should not stop treatment because of the 
worry of atypical femur fracture, which is a rare 
occurrence. Patients who decide to stop treatment 
should be monitored for recurrence of bone loss 
with biochemical BTMs and/or serial BMDs for 
decision of resumption of therapy.
2. Intravenous bisphosphonate
2.1 In the HORIZEN-PFT 3-year Extension Study, women 
who were randomised to continue zoledronic acid 
treatment for 3 additional years had stable BMDs at 
all sites, whereas women who were randomised to 
stop treatment after 3 years showed a slight drop 
in BMDs at all sites, but theses values remained 
above pretreatment levels. Biochemical markers 
remained constant in the former group, but rose 
slightly in the latter group, remaining well below 
pretreatment levels in both groups.148
2.2 Risk of new morphometric vertebral fracture was a 
significant 49% lower in the 6-year treatment group, 
while risks of other fractures were not different.148
2.3 A post-hoc analysis showed that the predictors for 
risk of new vertebral fracture were low achieved 
femoral neck or total hip BMD T-score (≤ –2.5) at 
the Extension Study baseline (OR=3.3 and 4.01, 
respectively) and incident vertebral fracture during 
the core study (OR=4.74).148 
2.4 Recommendations: The benefit of continued 
vertebral fracture risk reduction suggests that 
women at high fracture risk, particularly for 
vertebral fracture, may benefit from continued 
treatment beyond 3 years, especially if the hip BMD 
T-score remains ≤ –2.5 after 3 years of zoledronic 
acid therapy or if they have an incident vertebral 
fracture.
(N) Effect of Anti-osteoporosis Drugs on 
Fracture Healing
1. Regeneration of bone after a fragility fracture 
occurs in three stages: inflammatory, reparative, 
and remodelling phases.
2. The initial inflammatory phase and subsequent 
bone formation during the reparative phase 
are largely osteoclast independent whereas the 
remodelling phase depends on osteoclast activity.
3. Antiresorptive medications would be expected to 
affect the remodelling phase, whereas anabolic 
agents would be expected to stimulate osteoblastic 
activity in the reparative phase.
4. Bisphosphonates
4.1 Experimental animal models have demonstrated 
that there is no evidence for a negative effect 
on callus formation. Bisphosphonate treatment 
is associated with increased callus size, and 
mineralisation, reduced callus remodelling and 
improved mechanical strength.243
4.2 The most reassuring clinical evidence came 
from the HORIZON-RFT in which zoledronic 
acid administered within 90 days after hip 
fracture surgery did not impair fracture healing. 
There was no association between the timing of 
bisphosphonate administration and the risk for 
delayed fracture repair.144
4.3 Preliminary clinical data suggested that 
bisphosphonates improved osseo-integration to 
facilitate implant fixation.244
5. Denosumab 
5.1 Experimental animal models have shown that 
denosumab, similar to bisphosphonates, delayed 
callus remodelling, with improved callus strength 
and stiffness.245
5.2 In the subset of 199 patients in the FREEDOM trial 
with incident non-vertebral fracture, the continued 
use of denosumab was not associated with delayed 
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healing or with any complications following 
fracture or surgical management.246
6. Teriparatide
6.1 Experimental animal models demonstrated 
that teriparatide enhances fracture healing by 
increasing mineralisation, BMD, and mechanical 
strength throughout the remodelling phase of 
fracture healing.247
6.2 Evidence from small RCTs showed a consistent 
positive impact of teriparatide at a daily dose of 20 
μg on clinical fracture healing and non-union.243,247
7. There have been no clinical randomised studies 
on the effect of raloxifene or strontium ranelate 
on fracture healing. Only isolated case reports 
supporting a positive impact of strontium ranelate 
and fracture healing and non-union are available.243
8. A Consensus Workshop of the International Society 
for Fracture Repair (ISFR) in 2009 recommended that 
the evidence base for secondary prevention should 
overwhelm the non-evidence–based concerns 
about the potential adverse consequences of 
pharmaceutical treatment of osteoporosis on 
fracture healing so that anti-osteoporosis therapy 
should not be withheld after a fracture occurs. 
Secondary prevention treatment should be 
implemented as soon as practical before discharge 
from the acute fracture ward.248
(O) Cost-effectiveness of Osteoporosis 
Treatment
1. A detail analysis of the health economics of each 
type of osteoporosis treatment is beyond the scope 
of the current guideline.
2. Firm conclusions on the relative effectiveness of 
different anti-osteoporosis therapies on fracture 
risk reduction cannot be confidently and accurately 
made without direct head-to-head comparison 
studies using fracture incidence as the endpoint.
3. In a summary of meta-analyses of therapies 
for postmenopausal osteoporosis, the NNTs in 
the high-risk population to prevent a vertebral 
fracture over a period of 2 years were 72, 96, and 
99 for alendronate, risedronate and raloxifene, 
respectively. The corresponding NNTs for 
prevention of a non-vertebral fracture were 24 and 
43 for alendronate and risedronate respectively.249 
The NNT would be expected to be lower for 
patients at higher risk or for treatment over longer 
periods of time.
4. Reports on cost-effectiveness analyses have 
also suggested that raloxifene was cost-effective 
for treatment of postmenopausal women 
at an increased risk of vertebral fracture,250 
and strontium ranelate was cost-effective for 
treatment of postmenopausal women with low 
BMD.251 Denosumab was also cost-effective when 
compared with no therapy or oral treatment, 
particularly for women at high risk of fracture252,253 
and low expected adherence to oral treatment252 or 
who are intolerant and/or have contra-indications 
for oral bisphosphonates.253
5. Studies on the cost-effectiveness of osteoporosis 
treatment in the local population are pending.
(P) Effect of Osteoporosis Treatment on 
Mortality
1. Excess mortality has been reported to be associated 
with both vertebral and non-vertebral fractures.8,9
2. A recent meta-analysis showed that older adults 
have a 5- to 8-fold increased risk for all-cause 
mortality during the first 3 months after hip 
fracture. Excess annual mortality persisted over 
time such that white women who had a hip fracture 
at the age of 80 years had excess annual mortality 
compared with white women of the same age 
without a fracture of 8%, 11%, 18% and 22% at 1, 2, 5 
and 10 years, respectively. Men were noted to have 
a higher mortality than women at any given age.254
3. The excess mortality was attributed to infection 
(hazard ratio [HR]=6.66) for women and cardiac 
diseases (HR=2.68) both for men and women 
in a prospective cohort study involving 229 
institutionalised elderly people with hip fracture 
matched to 229 controls.8
4. Survival benefit with osteoporosis treatment was 
first demonstrated in the HORIZON-RFT in which 
zoledronic acid infusion administered within 90 
days after hip fracture surgery was associated with 
a 28% reduction in all-cause mortality in a group of 
1065 men and women followed up for a median of 
1.9 years.144
5. Although most previous clinical trials were not 
powered to detect mortality differences, a meta-
analysis of >1400 deaths in >40 000 patients in 
10 clinical studies of five agents (alendronate, 
risedronate, strontium ranelate, zoledronic 
acid, and denosumab) showed that treatment of 
osteoporosis was associated with a significant 10% 
reduction in mortality. The mortality reduction 
was mainly observed in studies of older, frailer 
individuals at high risk of fracture.255
6. Cohort studies also provide evidence of improved 
survival with osteoporosis treatment. In the 
prospective Australian Dubbo Osteoporosis 
Epidemiology Study, the use of oral bisphosphonate 
therapy was associated with an observed reduction 
in mortality up to 70% in elderly women and 50% 
in elderly men when compared with the general 
population. However, treatment with hormone 
therapy or calcium with or without vitamin D did 
not improve survival.256
7. Pooled analyses also showed that all-cause mortality 
was 10% lower among postmenopausal women 
receiving raloxifene compared with placebo, due 
primarily to reduction in non-cardiovascular and 
non-cancer deaths.257
8. The mechanism by which deaths are prevented 
with osteoporosis treatment is not clear. Prevention 
of fracture seems to explain only a small proportion 
(2-8%) of the observed mortality reduction.256,257
9. The reduction in mortality with effective 
osteoporosis treatment, when added to the 
established reduction in morbidity from such 
treatment, provides another important reason for 
vigorous intervention for frail elderly patients at 
high risk of osteoporotic fracture.
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(Q) Management of Osteoporotic Fractures
1. Management of osteoporotic vertebral compression 
fractures
1.1 Osteoporotic vertebral compression fractures are 
the most common osteoporotic fractures and may 
be asymptomatic at initial presentation.
1.2 A common presentation is sudden onset of back 
pain immediately or shortly after relatively mild 
trauma. The most frequent location is at the 
thoracolumbar junction. Referred pain to the 
lower back is also common. The presence of local 
tenderness at the thoracolumbar junction may help 
to locate the source of pain.
1.3 Clinical consequences may include chronic 
disabling pain, spinal deformity with round 
kyphosis at the thoracolumbar spine, pulmonary 
dysfunction, loss of mobility, gross impairment in 
activities of daily living, psychosocial disturbance, 
notably depression, and excess long-term mortality. 
Most patients, however, recover without significant 
sequelae.
1.4 The diagnosis can usually be established by plain 
radiographic examination, as follows:
 (i) for acute fracture, there may be well-
demarcated fracture lines or cortical breakage
 (ii) for old healed fracture, sclerosis, dense 
cortical margin, or osteophytes may be seen
 (iii) presence of pedicle spreading suggests burst 
fracture secondary to more severe trauma
 (iv) presence of intravertebral clefts is associated 
with gross instability. Patients may be 
symptomatic and the possibility of non-union 
is higher
1.5 MRI examination may reveal impending 
osteoporotic collapses before X-ray changes are 
visible. MRI may also be useful to exclude neoplasm 
or infection and assist with preoperative planning if 
patients have significant neurological deficits.
1.6 Conservative management results in improvement 
of symptoms over 6-8 weeks in the majority of 
patients:
 (i) a short period of bed rest for no more than a 
few days
 (ii) adequate analgesics for pain relief; morphine 
or other potent analgesics may occasionally 
be required
 (iii) encouragement for gradual mobilisation after 
an initial period of acute pain
 (iv) thoraco-lumbo-sacral orthosis may further 
help pain control and mobilisation
1.7 Patients who fail conservative treatment may 
be considered for vertebral body augmentation 
procedures (refer to Section Q2: Vertebral body 
augmentation: vertebroplasty and kyphoplasty on 
this page) or open surgery.
1.8 Open surgical intervention is usually indicated 
for patients with significant neurological deficits, 
progressive and severe kyphotic deformity or 
intractable pain (despite vertebral augmentation). 
The neurological deficit is either a result of spinal 
instability or nerve compression by bony fragments.
1.9 The objectives of surgery are stabilisation and 
decompression. Surgeons should carefully balance 
the risks and benefits of surgery.
1.10 Common surgical procedures include reduction 
osteotomy, combined anterior and posterior column 
reconstruction through the posterior approach and 
posterior instrumentation coupled with cement 
vertebral augmentation. Combined anterior and 
posterior spinal column reconstruction gives the 
strongest stability that decreases the possibility 
of instrumentation failure in osteoporotic bone. 
To reinforce the posterior anchors, surgeons can 
combine pedicle screw fixation with kyphoplasty 
or vertebroplasty. In addition, surgeons can use 
a combination of hooks, pedicle screws, and 
sublaminar wires to increase the strength of the 
construct.
2. Vertebral body augmentation: vertebroplasty and 
kyphoplasty
2.1 Either vertebroplasty or kyphoplasty offers an 
alternative minimally invasive procedure for 
treatment of painful osteoporotic compression 
fractures that do not respond to conservative 
treatment.
2.2 Vertebroplasty involves percutaneous 
injection of 4-6 mL of acrylic bone cement, 
(polymethylmethacrylate) directly into the 
fractured vertebral body under imaging guidance; 
fracture reduction is also partially achieved 
through intra-operative positioning. A vast majority 
of patients (70-90%) with osteoporotic fractures 
report significant and durable pain relief at the 
treated levels, with improvement of function and 
mobility.258
2.3 Kyphoplasty is similar to vertebroplasty, but there 
is an additional procedure of insertion of a balloon 
tamp. When inflated with radiocontrast medium, 
the balloon compacts the cancellous bone and 
re-expands the collapsed vertebral body so that 
some correction of the kyphotic deformity can 
be achieved. This will be followed by injection of 
bone cement to provide structural support. Early 
reports have demonstrated a 90% symptomatic 
and functional improvement rate. Kyphoplasty 
may offer an additional advantage of realigning 
the sagittal balance of the vertebral column and 
restoring the height of the vertebral body.258
2.4 A meta-analysis involving 74 vertebroplasty and 35 
kyphoplasty studies, none of which were double-
blinded RCTs, showed that vertebral augmentation 
resulted in superior pain control within the first 
2 weeks of intervention compared with optimal 
medical management. Improvement of physical 
disability, general health, and pain relief were 
also better 3 months after intervention both for 
vertebroplasty and for kyphoplasty.259
2.5 Three open-label RCTs have shown either 
vertebroplasty or kyphoplasty achieved superior 
short-term pain improvement within 1-2 months, 
and improvement of quality of life and function 
measures of up to 12 months in patients with acute 
painful vertebral fractures compared with non-
surgical management.260-262
2.6 However, two double-blind RCTs with both control 
groups receiving a sham procedure showed that 
improvements in pain and pain-related disability in 
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patients treated with vertebroplasty were similar to 
the control groups at all time points from 1 week 
to 6 months in the first study and at 1 month in the 
second study.263,264
2.7 These two double-blind RCTs have been heavily 
criticised because of significant patient selection 
bias, in that those patients in greatest pain were 
excluded, which served to decrease the measured 
treatment effect and efficacy of vertebroplasty.265
2.8 While awaiting results of studies with more 
appropriate patient selection, vertebroplasty or 
kyphoplasty should remain a treatment option for 
highly selected patients with recent fractures and 
severe intractable pain that cannot be relieved by a 
reasonable period of conservative treatment.265
2.9 The most common complication is asymptomatic 
cement leakage, which occurs in 30-67% of 
vertebroplasties and 9% of kyphoplasties, but 
neurological complications such as radiculopathy 
and spinal cord compression are rare (0.6% 
for vertebroplasty and 0.03% for kyphoplasty). 
Pulmonary embolism is also rare (0.6% for 
vertebroplasty and 0.01% for kyphoplasty). Other 
complications such as epidural haematoma and 
infection are not common.258,266
3. Management of hip fractures
3.1 Despite advances in medical and surgical 
management, hip fracture is associated with high 
mortality and morbidity.7 This is partially related 
to the high prevalence of concurrent medical co-
morbidities and complications.
3.2 The vast majority of hip fractures in elderly patients 
should be treated by surgery because the results 
for surgery are much better than those for non-
operative treatment in terms of functional recovery, 
pain relief, and avoidance of complications.267
3.3 Non-operative management with prolonged bed 
rest and traction remains an option only for truly 
non-ambulatory, demented patients, or those with 
life-threatening co-morbidities.268
3.4 Fracture reduction and internal fixation is usually 
chosen for undisplaced femoral neck fractures in 
relatively young patients (<70 years).269 Both sliding 
hip screw and multiple cancellous screw fixation 
are effective methods.269 Joint replacement or 
arthroplasty is usually chosen for displaced femoral 
neck fractures in older patients (>70 years).267
3.5 Sliding hip screw or intramedullary nailing is 
the treatment of choice for intertrochanteric 
fractures.270
3.6 Operations should be performed within 24-48 
hours of admission, after essential preoperative 
workup.271,272 Pre-existing medical conditions such 
as electrolyte imbalances, significant anaemia, and 
bleeding tendency should be corrected before 
surgery. However, since hip fracture surgery is not 
an elective procedure, it is not necessary to perform 
extensive medical workup or to pursue unrealistic 
medical goals that may lead to unnecessary delay.273
3.7 The presence of any surgical complications (eg 
failure of fixation, infection) invariably leads to 
poor outcome.269,270,274 Hence, hip fracture surgery 
should be performed by experienced surgeons or 
under their direct supervision.
3.8 Nutritional assessment for hip fracture patients, 
with appropriate dietetic interventions such 
as supplementation with high-energy protein 
preparations containing minerals and vitamins, 
should be considered.
3.9 Pressure sore prevention is an important element of 
hip fracture rehabilitation. Patients should receive 
risk assessment with appropriate prevention and 
management strategies implemented.
3.10 The implementation of a geriatric hip fracture clinical 
pathway with early and active multidisciplinary 
involvement may improve the clinical outcomes of 
geriatric hip fracture.275
4. Management of wrist fractures
4.1 Wrist fracture commonly occurs as a result of a 
fall with an outstretched hand in an osteoporotic 
patient.
4.2 The usual treatment for these fractures is non-
operative, with manipulation and cast application 
for 4-6 weeks,276 despite the fact that most of these 
fractures will heal with significant shortening 
and malalignment.277 The consensus that the 
compromise in function will not be too significant 
for patients with low functional demand is generally 
accepted.278
4.3 With the introduction of new locking screws and 
fixed-angle metal implants, good alignment can 
often be achieved and maintained by placing a 
fixed-angle plate in the volar side of the wrist.279 This 
treatment method permits early wrist rehabilitation 
without the need for additional splinting, which 
makes it easier for elderly patients to resume 
activities of daily living earlier than they would be 
able to after prolonged immobilisation.
4.4 As more elderly people are enjoying an active 
lifestyle, the physical and psychological demands 
of a patient must also be taken into consideration 
when deciding whether early operative intervention 
should be performed.280
(R) Rehabilitation of Osteoporotic Fractures
1. General principles of rehabilitation
1.1 Osteoporosis rehabilitation involves prevention of 
fractures in osteoporotic patients and rehabilitation 
management after occurrence of fractures. The 
role of exercise cannot be overemphasised.
1.2 Physical activities and exercise modestly help to 
reduce bone loss in elderly people.79 In addition 
to their effect on bone mass, physical activities and 
exercise benefit the whole person by enhancing 
cardiovascular fitness, improving balance and 
posture, decreasing the risk of fall, increasing 
flexibility of soft tissues, decreasing depression, 
and generally providing a better quality of life.
1.3 Fall appears to precede the majority of fractures, 
notably hip and wrist fractures. Public awareness 
and prevention of fall among elderly people is an 
important element of osteoporosis management.
1.4 Physical activity and an active lifestyle should 
be encouraged in the community, including for 
patients with osteoporosis. Inactivity purely due to 
fear of a fall should be discouraged.
1.5 Rehabilitation of osteoporotic fractures aims to 
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maximise individual activity, participation (social 
position and roles) and quality of life, and minimise 
distress to caregivers.
1.6 Adequate pain control, minimisation of bed 
rest or inactivity with early mobilisation, early 
multidisciplinary rehabilitation with attention to 
a patient’s needs and environmental contextual 
factors are common keys to success in osteoporotic 
fracture rehabilitation.
2. Physical activities and exercise
2.1 The importance of exercise in prevention of 
osteoporosis has been outlined in Section G5 
(Exercise) on page 14.281-284
2.2 Weight-bearing, strength-training, and balance-
training exercises are important elements of an 
osteoporosis treatment programme.
2.3 Specific exercises that strengthen back extensor 
muscles and those improving strength around the 
shoulder blades, flexibility, balance, and posture 
may be helpful.
2.4 Certain types of exercise are contra-indicated for 
osteoporotic patients to avoid excessive stresses 
on the weaker bones. These include exercises 
with explosive movements or high-impact loading 
or those causing excessive twisting, flexion or 
compression of the spine, eg sit-ups, stomach 
crunches, and toe touches.
2.5 Maximal muscle strength training may not be 
appropriate for patients with severe osteoporosis. 
During treadmill walking, patients with significant 
vertebral fractures may have balance problems 
due to a forward shift of their centre of gravity. 
Alternative training with cycle ergometry may be 
more appropriate.
2.6 Non-weight–bearing or low-impact exercises, 
despite their uncertain effects on bone mass, may 
help to improve balance and coordination and 
maintain muscle mass, which can help to prevent 
falls.
2.7 Immobilisation and bed rest must be discouraged. 
Older adults, including those with chronic 
illnesses and disabilities, are encouraged to 
remain active as far as their health condition 
allows. They should adjust their physical activity 
levels appropriate to their fitness condition. They 
should consult rehabilitation specialists or health 
care professionals who can prescribe exercise 
programmes appropriate to their illnesses and 
abilities, and help them increase physical activity 
and function in a safe manner.
2.8 For those patients who cannot engage in regular 
physical activities due to disability, specially 
designed individualised rehabilitation and exercise 
programmes aiming at increasing activity and 
function are important.
2.9 Osteoporotic patients should be educated on the 
correct mode of performing their activities of daily 
living, eg bending at the trunk to pick up objects 
must be avoided to prevent vertebral compression 
fractures.
3. Fall prevention
3.1 Fall appears to precede the majority of fractures, 
notably hip and wrist fractures. While it may not be 
possible to prevent falls completely, interventions 
may help older people fall less frequently. An active 
approach against fall prevention should receive 
at least as much attention as drug therapy for 
osteoporosis.
3.2 A report from the Elderly Health Services of the 
Department of Health published in 2003 revealed 
that 18% of elderly people aged 70 years or older 
reported a history of falls, 6% of which resulted 
in fracture.285 Female sex, history of repeated falls, 
musculoskeletal problems, urinary incontinence, 
depressive mood, and poor financial state were 
identified as the most important risk factors for 
fall.285
3.3 Fall occurs as a result of the interplay between a 
patient and environmental factors. It is logical that 
fall prevention and intervention measures should 
be targeted at both dimensions.
3.4 Key strategies for prevention and management 
of elderly falls, as recommended by local or 
international authorities, are outlined below.286-291
    3.4.1 Comprehensive multi-factorial fall risk 
assessment and intervention can reduce falls.
    3.4.2 Both acute and chronic medical risk factors 
predisposing elderly people to fall should be 
identified and treated early.
    3.4.3 Effective exercise programmes incorporating 
training in balance, gait, coordination, and 
muscle strengthening should be offered to 
elderly people with high fall risk. Flexibility 
and endurance training should also be 
offered. Multiple-component group exercise, 
Tai Chi, or individually prescribed multiple-
component home-based exercises are 
effective in preventing falls.
    3.4.4 Assessment of the sensory systems, 
especially visual and vestibular functions, 
proprioception and hearing are important. 
Cataract is a common correctable cause of 
impairment of vision in elderly people. A 
recent observational study reported that 
elderly cataract patients who had cataract 
surgery had lower odds of hip fracture within 
1 year after surgery.292
     3.4.5 Neuromusculoskeletal conditions such as 
Parkinson’s disease, stroke, and arthritis 
need to be evaluated and treated with 
appropriate rehabilitation input. Assessment 
of parameters such as muscle strength, lower 
extremity, peripheral nerves, reflexes and tests 
of cortical, extra-pyramidal and cerebellar 
functions, gait and balance, and lower 
extremity joint function should be included.
    3.4.6 Assessment of mental status and cognitive 
function, psychological status, confidence 
and fear of fall, and risky behavioural issues 
are essential.
    3.4.7 Cardiovascular assessment is important for 
syncopal falls, for which further investigations 
such as the tilt-table test may be considered, 
as appropriate.
    3.4.8 Foot conditions, including footwear and 
mobility aids, should be assessed.
    3.4.9 Medications need to be reviewed regularly 
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to minimise side-effects that may increase 
the risk of fall. Withdrawal or minimisation 
of psychoactive medications is especially 
important. Postural hypotension due to over-
energetic treatment of hypertension should 
be avoided.
     3.4.10 Continence problems should be assessed and 
managed accordingly. Diuretics should be 
kept to the minimum doses in patients with 
urge incontinence.
    3.4.11 Elderly people with balance problems should 
be prescribed appropriate walking aids, and 
balance and gait-training exercises. Proper 
walking-aid use with good compliance should 
not be neglected.
    3.4.12 Population-based multi-strategy, multi-
focused programmes could help to prevent 
fall-related injury and may serve as the basis 
of public health practice.
    3.4.13 Supplemental vitamin D intake in adequate 
dosages or an adequate serum vitamin D 
concentration is associated with fewer falls.58
    3.4.14 Elderly people with risk factors for, or 
known history of, fall should be assessed 
by rehabilitation physicians, geriatricians, 
appropriate professionals or multi-disciplinary 
centres with expertise in fall management for 
proper training and rehabilitation. The service 
may be provided in the context of a fall clinic.
    3.4.15 When there is a history of fall, the fall 
circumstances, including time, place and 
activity at the time of the fall, triggering 
causes and consequences, should be 
comprehensively evaluated. Proxy interviews 
may help if the patient cannot give a reliable 
history.
    3.4.16 Hip protectors are useful for hip fracture 
risk reduction for institutionalised elderly 
people. The effectiveness of hip protectors 
for community dwelling elderly people is 
less clear.293 No important adverse effects 
of hip protectors have been found, but low 
compliance, particularly in the long term, is 
a major problem. Reasons for not wearing 
hip protectors include discomfort, extra 
time needed to put on the device, urinary 
incontinence, physical difficulty, or illness. 
A local study involving 654 institutionalised 
elderly people showed that compliance with 
a specially designed hip protector adapted to 
the Chinese body build varied from 55-70% 
at 1 year and hip protectors achieved an 82% 
reduction in the risk of hip fracture compared 
with matched controls.294
    3.4.17 A safe home and community benefits 
all. Despite difficulties in establishing its 
effectiveness in fall prevention, home and 
environmental safety should be emphasised, 
especially for those at higher risk for fall. 
Adverse environmental hazards such as poor 
lighting, and slippery or irregular floor surfaces 
should be corrected. Special attention should 
be paid to risk factors that may not be obvious 
at initial assessment, eg slippery footwear, 
misplaced toys, and wet floors.
    3.4.18 Fall prevention education programmes may 
be useful.
    3.4.19 Caregivers should be aware of the risk of fall 
and educated on the correct techniques for 
transfer of elderly people to avoid fall and fall-
related injuries.
(S) Conclusions
1. There has been a vast quantity of information in the 
field of osteoporosis published in the literature in 
the past decade.
2. This Guideline aims to summarise the current 
understanding of the disease, with special emphasis 
on aspects relating to the anti-osteoporosis 
medications currently available, and potential 
adverse effects and existing controversies so that 
the Guideline can serve as an updated reference 
for local specialists and primary care practitioners 
for management of patients with postmenopausal 
osteoporosis in their clinical practice.
3. The choice of anti-osteoporosis medication may be 
influenced by the age of a patient, co-morbidities, 
anti-fracture efficacy, potential adverse effects and 
affordability of individual medications and, most 
importantly, the preference of individual patients.
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